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Abstract 
For decades, phthalates are widely used as plasticizers in plenty of consumer 
products e.g. food packaging, toys, clothing and personal care products. They are not 
chemically bound to the polymer matrix, so they can easily be released into the 
environment for example by leaching or migration. Humans are exposed to 
phthalates via ingestion, inhalation or dermal uptake. They are rapidly metabolized in 
humans and excreted via urine, mainly within two days. Phthalates act as endocrine 
disruptors and target mainly the reproductive system. According to US-Environmental 
Protection Agency (US-EPA), infants have an unintended uptake of 60 mg dust per 
day. Among other things, dust contains a various amount of pollutants as e.g. 
phthalates. Therefore, dust could pose a potential health risk to humans. Currently 
there are no information’s about the bioavailability of phthalate in dust. Consequently 
in risk assessments the bioavailability is determined as 100 %. In the case of 
phthalates, in vitro digestion tests are indicating a bioaccessibility of 10 – 32 %. The 
aim of this study was to determine the relative oral bioavailability of certain phthalates 
as butyl benzyl phthalate (BBzP), bis (2-ethylhexyl) phthalate (DEHP), di-n-butyl 
phthalate (DnBP) and di-isononyl phthalate (DINP) in house dust after oral ingestion.  
Study design: Seven five week old piglets were fed five different dust samples 
collected from daycare centers and one food sample. Overall, 0.43 to 0.83 g of dust 
samples sieved to 63 µm were administered orally. The urine was collected over a 
period of 38 hours. The excreted metabolites were quantified using an LC-MS/MS 
method.  
Results: The mean uptake rate of the applied dust dose for BBzP, DnBP, DEHP and 
DINP is 28 ± 18 %, 52 ± 18 %, 43 ± 11 % and 47 ± 26 %, respectively. The 
bioavailability in food is 37 ± 23 % for BBzP, 39 ± 16% for DnBP, 53 ± 15 % for 
DEHP and 43 ± 13 % for DINP. No significant difference between the quantities of 
plasticizers excreted in urine after dust administration compared to food was 
observed. The metabolites showed their maximum concentration three to five hours 
post dose.  
Conclusion: The bioavailability of the investigated phthalates is much higher 
compared to the bioaccessibility reported from in vitro digestion tests. Furthermore it 
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is noticeable that the bioavailability of DEHP does not vary between the dust 
samples. A dose dependent saturation process for DINP was observed. Besides 
other intake pathways, dust could pose a relevant source of phthalates for toddlers.  
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Zusammenfassung 
Seit Jahrzenten werden Phthalate in großen Mengen als Weichmacher in 
(Lebensmittel-) Verpackungsmaterial, Spielzeug oder Kleidung eingesetzt und zählen 
daher zu einer der wichtigsten Industriechemikalien. Phthalate sind nicht an die 
Polymermatrix gebunden und können durch (Ab-)Nutzung relativ leicht in die Umwelt 
abgegeben werden. Phthalate werden als endokrin aktive Substanzen eingestuft und 
haben eine negative Wirkung auf das Reproduktionssystem. 
Kleinkinder nehmen oral täglich 60 mg unbeabsichtigt Hausstaub auf. In Hausstaub 
kommen teils hohe Konzentrationen an Schadstoffen, wie z.B. Phthalate, vor. Derzeit 
gibt es keine Kenntnisse über die orale Bioverfügbarkeit von Weichmachern in der 
Matrix Staub. In einem in vitro Verdauungstest konnte eine Bioverfügbarkeit von 
Phthalaten aus dem Staub zwischen 10,2 % (DEHP) und 32 % (DMP) nachgewiesen 
werden. In dieser Studie soll anhand eines Tierversuchs die orale Bioverfügbarkeit 
von Butylbenzylphthalat (BBzP), Bis (2-ethylhexyl)phthalat (DEHP), Di-n-
butylphthalat (DnBP) und Di-isononylphthalat (DINP) in Hausstaub und 
Lebensmitteln untersucht werden. 
Studiendesign: Sieben fünf Wochen alte Schweine erhielten jeweils fünf 
unterschiedliche Hausstaubproben (Staub aus Kindertagesstätten auf 63 µg gesiebt; 
verabreicht: 0,43-0,83g) und eine Lebensmittelprobe. Der Urin wurde über 38 
Stunden gesammelt. Die ausgeschiedenen Metabolite wurden mittels einer LC/MS-
MS Methode bestimmt. 
Ergebnisse: Die durchschnittliche Aufnahme von BBzP, DnBP, DEHP und DINP im 
Staub lag bei 28 ± 8 %, 52 ± 18 %, 43 ± 11 % und 47 ± 26 %. Bei der 
Lebensmittelprobe lag sie bei 37 ± 23 % für BBzP, 39 ± 16 % für DnBP, 53 ± 15 % 
für DEHP und 43 ± 13 % für DINP. Es konnte kein signifikanter Unterschied bei der 
Aufnahme zwischen Hausstaub und Lebensmittelprobe nachgewiesen werden. Das 
Konzentrationsmaximum der Phthalatmetabolite im Urin konnte drei bis fünf Stunden 
nach der Probengabe festgestellt werden.  
Schlussfolgerung: In dieser Studie konnte gezeigt werden, dass die Bioverfügbarkeit 
- je nach Weichmacher im Hausstaub - bei ca. 40 % liegt und somit höher als in den 
in vitro Verdauungstests (10 – 20 %). Außerdem zeigte sich, dass die 
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Bioverfügbarkeit von DEHP innerhalb der getesteten Staubproben stabil und 
reproduzierbar ist. Bei DINP konnte ein dosisabhängiger Sättigungsprozess 
festgestellt werden. Zusammenfassend lässt sich sagen, dass Staub eine 
Expositionsquelle bei Kleinkindern darstellt.
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Abbreviation 
µg/kg/d Microgram per kilogram per day 
2cx-MMHP Mono-(2-carboxymethyl)hexyl phthalate 
5OH-MEHP Mono-(2-ethyl-5-hydroxylhexyl) phthalate 
5oxo-MEHP Mono-(2-ethyl-5oxohexyl) phthalate 
5cx-MEPP Mono-(2-ethyl-5carboxypentyl) phthalate 
7oxo-MINP Mono-(4-methyl-7oxo-octy)l phthalate 
7cx-MINP Mono (4-methyl-7-carboxy-heptyl) phthalate 
7OH-MINP Mono-(4-methyl-7-hydroxyoctyl) phthalate 
95th P 95th percentile 
ADD Average daily dose 
AGD Anogenital distance 
b.w. Body weight 
BBzP Butyl benzyl phthalate 
Cmax Concentration maximum 
DEHP Bis (2-ethylhexyl) phthalate 
DINP Diisononyl phthalate 
DnBP Di-n-butyl phthalate 
EDCs Endocrine Disrupting Chemicals 
EU European Union  
FSH Follicle stimulating hormone 
GC/MS Gas chromatography–mass spectrometry 
HMW High molecular weight 
HPLC High-performance liquid chromatography 
IgE Immunoglobulin E 
IgG Immunoglobulin G 
Kow N-octanol/water coefficient 
LC-MS Liquid chromatography–mass spectrometry 
LMW Low molecular weight  
LOD Limit of detection  
LOQ Limit of quantitation  
MBzP Mono-benzyl phthalate 
MED Median 
MEHP Mono (2-ethylhexyl) phthalate 
mg/d Milligram per day 
MIN-MAX Minimum–maximum  
MINP Mono-isononyl phthalate 
MnBP Mono-n-butyl phthalate 
NOAEL No observed adverse effect level 
PBDE Polybrominated diphenyl ethers 
PVC Polyvinyl chloride 
RfD Reference dose 
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t½ Half-life time 
T3 Triiodothyronine 
T4 Thyroxine 
TDI Tolerable daily intake 
Th2 T helper cells 2 
Tmax Time after sample administration, when the maximum urine 
concentration is reached 
TSH Thyroid stimulating hormone 
US-EPA United states environmental protection agency  
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1I Introduction  
1I1 Phthalates 
Synthetic chemical diesters of 1,2-benzenedicarboxylic acid (Figure 1), commonly 
known as phthalates, are widely used in the chemical industry as plasticizers to 
increase the flexibility and softness in plastic, e.g in polyvinyl chloride (PVC). 
Plasticizers can represent up to 40% of plastic products [1]. In addition to PVC 
products, phthalates are present in various consumer products like personal care 
products, children’s toys, food packaging, building materials, clothing, medical 
devices and in pharmaceutical products [2, 3]. There are more than 25 different 
phthalates in technical use. Table 1 gives an overview of the phthalates and their 
characteristics on which this study focuses.  
 
Figure 1. Molecular structure of phthalate esters, R and R1 are alkyl and aryl chains with the same or 
different structures [3]. 
 
Phthalates are categorized in two groups based on physiochemical properties: 
 Low molecular weight (LMW) phthalates: produced from alcohols with a straight 
chain of one to four carbon backbones. These are primarily used in 
pharmaceuticals and personal care products as a solvent, e.g. in fragrances, 
soaps, lotions etc. LMW phthalates are slightly to moderately water soluble [3, 
4]. 
 High molecular weight (HMW) phthalates: produced from alcohols with a straight 
chain or ring structure of five or more carbon backbones. These kinds of 
phthalates are primarily used as plasticizers in vinyl products such as flooring, 
wall covering, medical devices and food contact material. HMW phthalates are 
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water insoluble, but soluble in most organic solvents like alcohol, ether and oils [3, 
4]. 
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Table 1: Overview of the investigated phthalates, their corresponding metabolites and their characteristic [3]
Phthalate Molecular 
Formula: 
CAS No. Backbone 
length 
Log 
Kow 
Metabolites  Uses 
Butylbenzyl 
phthalate 
(BBzP) 
C19H20O4 85-68-7 C4,C5 4.48 Mono-benzyl phthalate (MBzP) Automotive adhesives, coating, sealants 
and paints, plasticizer in children’s toys, 
Di-n-butyl 
phthalate 
(DnBP) 
C16H22O4 84-74-2 C4 4.57 Mono-n-butyl phthalate (MnBP) Plasticizer for rubber, adhesives in textiles 
and leather treatments, children’s toys, 
fragrance bases for household, personal 
care and cosmetic products 
Diethylhexyl 
phthalate 
(DEHP) 
C24H38O4 117-81-7 C6 7.50 Mono-(2-ethylhexyl) phthalate 
(MEHP)  
Mono-(2-ethyl-5-hydroxylhexyl) 
phthalate (5OH-MEHP)  
Mono-(2-ethyl-5oxohexyl) phthalate 
(5oxo-MEHP) 
Mono-(2-ethyl-5carboxypentyl) 
phthalate (5cx-MEPP) 
Mono-(2-carboxymethyl)hexyl 
phthalate (2cx-MMHP) 
 
In coating, adhesives and resins for 
flooring, PVC labels, fragrance bases for 
perfumery and cosmetic products 
Di-isononyl 
phthalate 
(DINP) 
C26H42O4 285533-12-0,  
68515-48-0 
C8;C9 8.8 Mono-isononyl phthalate (MINP) 
Mono-(4-methyl-7oxo-octyl) 
phthalate (7 oxo-MINP) 
Mono-(4-methyl-7-hydroxyoctyl) 
phthalate (7OH-MINP) 
Mono (4-methyl-7-carboxy-heptyl) 
phthalate (7cx-MINP) 
Plasticizer for PVC applications, flooring, 
carpet backing, lamination, toys 
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Di-2-ethylhexyl phthalate (DEHP) and Di-isonyl phthalate (DINP) are the principally 
used phthalates in industry [5]. In the European Union, the use of DEHP, DEP and 
DnBP is banned and often replaced by substitutes like DINP, which now accounts for 
80% of the phthalate production in Europe [6]. Because of their extensive use and 
the resulting permanent presence in the environment, phthalates are substances of 
concern [7]. 
 
1I1I1 Toxicokinetics of phthalates 
The majority of phthalate uptake takes place after oral ingestion. Once incorporated 
in the human body, phthalates are rapidly metabolized and excreted via urine. 
Phthalates undergo a biotransformation, which can be categorized in two phases:  
Phase 1: Phthalates are metabolized into their corresponding mono-ester (primary 
metabolite) by hydrolysis of one of their ester bonds. The monoester of high 
molecular weight phthalates undergoes a further enzymatic oxidation of the alkyl 
chain and is finally metabolized to more hydrophilic metabolites (secondary 
metabolites).  
Phase 2: also known as conjugation reaction; the primary or secondary metabolites 
conjugate with glucuronic acid and/or sulfate, both increase the water solubility and 
might reduce the biological activity of the phthalate metabolites. The glucuronide 
conjugate is finally excreted mainly with urine. The conjugation reaction is catalyzed 
mainly by the enzyme uridine diphosphate glucuronosyltransferase (UGT) [3].  
 
The amount of oxidative metabolites depends on the alkyl chain length of phthalates 
because oxidative metabolites are more water soluble than monoesters. Water 
solubility decreases relative to increasing alkyl chain length. As a consequence, low 
molecular weight phthalates are mainly metabolized to monoesters (primary 
metabolite), whereas high molecular weight phthalates like DEHP or DINP mainly 
transform their monoester in a second step to oxidative metabolites and excrete them 
as secondary metabolites [8, 9]. Only 2 – 7 % of the applied dose of high molecular 
weight phthalates is excreted as their primary metabolite [10].  
In the human body, phthalates are absorbed by the gastrointestinal tract, where they 
are metabolized to the corresponding monoester, which is then further transported to 
the liver. The monoester is transformed to the secondary metabolites mainly in the 
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liver. After that, the primary or secondary metabolites are transported to the kidneys 
where they are excreted by urine [11, 12]. During the urinary excretion, there are 
several maximums of metabolite elimination. The metabolism of phthalates is 
biphasic with a fast elimination rate within the first 24 hours after dose administration 
followed by a slow elimination rate. Most of the applied dose is excreted within the 
first 48 hours [13].  
Although the urinary excretion in humans has a high individual variation of phthalates 
and their metabolites content, the ratio of hydrolytic and oxidative metabolites from 
the parent compound are highly stable in urine [14].  
The individual metabolism of the investigated phthalates in this study is discussed in 
detail in Section 1I2I5.  
 
1I1I2 Exposure and migration of phthalates  
1I1I2I1 Routes of exposure 
Due to their chemical and physical properties, phthalates are not chemically bound to 
the polymer, which means that they can be easily released into the surroundings by 
leaching, evaporation, migration and abrasion from the polymer matrix during usage 
[3, 4, 10]. Additionally phthalates are lipophilic, which can be an influencing factor in 
their leaching and environmental distribution behavior [9]. Based on their semi- to 
non-volatile characteristics, phthalates are mainly bound to particles like in dust 
instead of staying in the gaseous phase [11].  
Humans are exposed to phthalates on a daily basis via several pathways like 
ingestion, inhalation (gaseous or particle bound), dermal absorption and intravenous 
injection [8]. Phthalate exposure can occur directly by using a product which contains 
phthalates, e.g. personal care products, or indirectly by a product where the 
phthalates are leached or migrate into, e.g. food through packaging material.  
• Ingestion: is the main route of exposure to phthalates. It occurs mainly via 
dietary intake and to lesser extent via pharmaceuticals, nutritional supplements, and 
mouthing or sucking children toys. The systemic bioavailability is assumed to be 50 
% for adults and 100 % for children / infants [15]. 
• Inhalation: occurs through house dust and also through medical devices, e.g. 
breathing tubes (bioavailability from 75 % (adults) to 100 % (children and infants) 
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• Skin absorption: occurs through direct contact with products like clothes, 
personal care products, etc. which contain phthalates. In general the absorption of 
phthalates through skin is limited (bioavailability lays around 5 %).  
• Intravenous: occurs through medical devices when phthalates migrate from 
e.g. infusion bags into the fluid which is intravenously administered to the patient [9].  
 
Ingestion of food containing phthalates and absorption through the use of personal 
care products are the major contributors to phthalate exposure, whereas inhalation is 
negligible [16].  
In addition to the different exposure pathways mentioned before, the phthalate body 
burden is influenced by hand to mouth activity, mobility, diet, personal care and 
hygiene practices. Therefore infants and toddlers have a higher risk of an increased 
phthalate intake than adults, based on their high food and water requirements per 
unit of body mass, their increased hand to mouth activity and their higher ventilation 
rate [17].  
 
1I1I2I2 Mouthing – another exposure pathway for infants 
Young children use mouthing as a part of exploring their environment. Mouthing is 
defined as activities where fingers or objects are put into the mouth or touched with 
the mouth, which includes licking, sucking, chewing, biting but excludes eating and 
drinking. An important and limiting factor of phthalates exposure is the duration of 
mouthing, which is equal to the exposure time. As demonstrated in studies [18, 19], 
mouthing objects like toys, fingers and pacifiers and mouthing time differ by age. 
Between 0 and 18 months the average mouthing time of toys is 20 mins, whereas 
between 18 and 36 months, it is only five minutes [20]. Sucking and licking behaviors 
are the most common way of mouthing. It was also shown that mouthing objects 
change by age. In the first three months, the main mouthing objects are fabrics (80 
%), while around 6 to 9 months, plastic toys account for 50 % of the objects mouthed 
and remain the main mouthing object until the age of five. A 6 to 9 months old child 
mouthed around 26 different items per day, whereas only 3 items were mouthed by a 
1 to 3 month old child. The highest mouthing time (5 hours) was found at age 6 to 9 
months and two year old children [18]. In general the hand to mouth frequency 
decreased by increasing age [21, 22]. Besides the age of the child and the duration, 
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another important factor of the frequency of mouthing is the location, indoor and 
outdoor. It was shown that indoor hand to mouth frequencies was 2.4 times higher 
than outdoors with two-year old children.  
In two meta-studies, Xue et al. [21, 23] calculated the frequency of hand to mouth 
and object to mouth. The average indoor hand to mouth contact for toddlers ranged 
between 12.7 and 19.6 contacts per hour, whereas the mean indoor object to mouth 
contact is higher and varies between 15 and 26.6 times per hour. At 1 to 2 years, the 
outdoor object to mouth rate was three times lower than the indoor rate. 
In addition to mouthing, crawling and sitting on the floor increases the accessibility to 
house dust. Compared to older children and adults, infants and toddlers have a 
greater exposure risk of indoor pollutants in dust.  
Including mouthing, the average daily dust ingestion of an infant or toddler is around 
50 mg/d whereas an adult only ingests around 1 mg/d [24, 25]. Furthermore, infants 
and toddlers could be exposed through using teething rings, pacifiers or the nipple of 
baby bottles, which could contain certain phthalates. Since 1999 the use of 
phthalates in certain baby articles were restricted to less than 0.1 % of the object 
weight [20].  
In conclusion, mouthing of objects, like toys etc. which contain phthalates or are 
covered by dust can be a potential source of the phthalates exposure for infants and 
toddlers.  
 
1I1I2I3 Phthalate migration  
The common method for measuring phthalate migration from toys to saliva is the 
head over heels agitation method. Five sample pieces 2 mm thick and 23 mm in 
diameter are removed from the surface of the investigated toy. Each piece is put in a 
flask which is filled with 25 ml of saliva simulant solution. In a head over heels rotator, 
this flask is rotated for 30 min at 60 rpm. After this, the saliva simulant solution was 
prepared for analyzing by HPLC or GC/MS [26] (detailed description in TNO Report 
[27]). Pfaff et al. [28] concluded in their migration experiment with plastic toys that the 
average DEHP and DINP migration was around 10 µg/cm²/h. In an in vivo 
experiment by Fiala et al. [29], the migration behavior of DINP was investigated by 
sucking and biting on a toothing ring. The result of that study showed that the 
average release of DINP through sucking was 1.38 µg/min/10cm², whereas when 
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chewing was included, it amounted to 2.22 µg/min/10cm². During this procedure 36 
% of the DINP content of the toothing ring was released. Furthermore, it showed that 
the migration behavior of DEHP is similar to DINP. The higher the DEHP and DINP 
content of a product, the higher the migration rate. In addition to the phthalate 
content, it has been concluded that the migration rate is also influenced by factors 
like surface roughness, coating type, thickness of the object, and the surrounding 
temperature [26, 30]. Further tests also showed that in a saliva simulant solution the 
migration rate was higher than in water and additionally that sucking and chewing 
increase the migration process compared to static conditions [29].  
 
1I1I2I4 Methods to calculate phthalate exposure and intake 
There are two tools to calculate the human phthalate exposure, biomarker studies 
and indirect studies. In biomarker studies, the total daily intake was back calculated 
using the metabolite concentration in urine. Whilst in the indirect studies, the 
concentrations in the environmental media and food combined with e.g. ingestion 
rates are used to calculate the phthalate intake. Biomarker studies are susceptible to 
physiology and do not provide any information about exposure sources. In addition, 
the toxicokinetic properties of each phthalate has to be known for an adequate 
calculation. In the indirect studies, the main focus is on dietary intake, which is 
calculated by a database of phthalate concentration in food. A few indirect studies 
include other pathways like inhalation or dermal contact [31].  
Clark et al. [31] performed a comparative study of biomonitoring and the indirect 
method and concluded that in many cases both methods agree with each other and 
discrepancies are explainable through regional differences, focusing on one 
metabolite, not including all pathways or lack of information. Both methods have their 
advantages as well as their disadvantages, but there is a tendency that for low 
molecular weight phthalates the biomarker method is a better choice, because for 
those phthalates is it difficult to identify all the exposure source, whereas for high 
molecular weight phthalates, either method is adequate. Furthermore, the indirect 
method is useful to detect new exposure sources while the biomarker method 
quantifies the amount of exposure.  
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For calculating phthalate intake, the following equations are used:  
The daily intake of phthalates is estimated by the following equation [32]:  
             
D = daily intake, C urine = metabolite concentration in urine in µg/l, UV = excreted urinary volume per 
day, Fue = molar fraction of excreted metabolites in relation to the corresponding parent compound, 
MWp = molecular weights of phthalates and MWm =molecular weight of the corresponding metabolite.  
 
To estimate the phthalate intake through dust ingestion the following formula is used 
[24]:  
             
Edust = phthalate intake caused by dust in mg/kg b.w. per day, Cdust: phthalate concentration in dust in 
mg/kg, qdust: amount of the daily dust ingestion in kg/d, ruptake: the fraction of the amount of phthalates 
transferred into the body.  
 
This equation can be modified for other ways of ingestion, e.g. food or exposure 
through toys.  
 
1I1I3 Health effects of phthalates  
Due to the extensive use of chemicals, the exposure of humans to various industrial 
chemicals has increased in the last decades. Several of such man-made substances 
have been shown to be toxic in animal studies and also have an impact on human 
health, respectively [33]. As shown in vivo and in vitro, several phthalates have an 
antiandrogenic activity and possible estrogenic actions and therefore phthalates are 
classified as endocrine disrupting/modulating agents, which target mainly the male 
reproductive system [16]. 
Endocrine-Disrupting Chemicals (EDCs) are natural or man-made substances which 
alter the normal function of the hormone system, by inhibition, mimicry or modification 
of the hormone. In addition, EDCs can modify the production of hormones in 
endocrinal glands and the metabolism of hormones [34].  
 
1I1I3I1 Reproduction and development 
Some phthalates cause reproductive and developmental toxicity. They are able to 
cross the placental barrier. Gestational exposure can reduce the Leydig cell 
testosterone production, which could cause malformation in genital development or a 
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shortened anogenital distance (AGD) [16]. In addition, it was discussed if 
abnormalities like hypospadias, cryptorchidism and malformation of the epididymis, 
vas deference, seminal vesicles and prostate are effects of the so- called “phthalate 
syndrome” or “testicular dysgenesis syndrome”. Especially DEHP, DnBP and BBzP 
are associated with these abnormalities [35].  
At the present state of knowledge, it is not clear if prenatal phthalate exposure is 
associated with gestational length or anthropometry of newborns. In recent years, 
several studies have been published, but the results are inconclusive [36, 37].  
 
Semen parameters  
The primary target of e.g. DEHP are Sertoli cells in the testes. Furthermore, it is well 
known that the metabolite MEHP is responsible for the effects in the testes. The 
Sertoli cells are an important part of spermatogenesis by determination of the amount 
of germ cells. The amount of Sertoli cells in an adult man is influenced by the 
proliferation of Sertoli cells in puberty. The Leydig cells, responsible for the 
production and secretion of testosterone and stimulation of sperm production, were 
also negatively affected by phthalates. It has been shown that DEHP and DnBP 
reduce sperm motility [3, 38]. Duty et al. [39] observed a dose response relation 
between MBzP (metabolite of BBzP) and sperm concentration and motility. 
Furthermore, a correlation between phthalate exposure and DNA damage in human 
sperm was reported. A repeated DEHP dose results in seminiferous tubular atrophy 
induced by the loss of meiotic and post meiotic cell populations in the seminiferous 
epithelium [3, 40, 41].  
Ovary 
Some phthalates are suspected of disrupting the development of ovaries and oocyte, 
acceleration of the primordial follicle recruitment, targeting growing follicles, inhibiting 
the growth of antral follicles, disrupting oocyte maturation and ovulation and altering 
the post-ovulatory process. Further, several studies indicated, that phthalates disrupt 
the production, action and secretion of several sexual hormones by altering mRNA, 
protein and steroidogenic enzymes, resulting in a decreased estradiol level. But the 
mechanism of action is still not clear and further research is needed [42]. 
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1I1I3I2 Thyroid hormone system  
The thyroid hormone system is involved in many physiological processes like 
metabolism, brain and organ development and fetal and child growth. Phthalates are 
suspected of affecting the thyroid signaling through various mechanisms, by 
interfering with the binding between T3 and transport proteins and the plasma 
membrane uptake of active T3, respectively. An inverse relationship between urinary 
DEHP-metabolites and total and free T4 levels, total T3, thyroglobulin and increased 
TSH level was observed. Those results indicated that phthalates negatively affect the 
thyroid system and metabolism, which can cause a negative impact for the 
developing fetus and growing child [16, 43, 44].  
 
1I1I3I3 Asthma and Allergies  
Phthalates have been associated with modulation of the immune system. Reviewed 
by Bornehag et al. [33], experimental studies showed that phthalates have an 
adjuvant effect on Th2 cells (differentiation or production) and enhanced the level of 
Th2 cells promoted immunoglobulins IgG and IgE. IgE has an essential role in 
allergies and asthma. Several epidemiological studies indicate a possible correlation 
between asthma, allergies, rhinitis, eczema or wheezing symptoms and phthalate – 
especially DEHP exposure [17]. Another study by Bornehag et al. [45] showed that 
high concentration of DEHP in house dust is associated with asthma and high levels 
of BBzP are related to allergic and eczematous symptoms.  
 
1I1I4 Biomonitoring data of phthalate levels in urine 
The Human Biomonitoring Commission advises two Human BioMonitoring values 
(HBM1 and HBM2) to assess the pollutant exposure in the general population. The 
HBM1 value is a control value, where no negative health effects are expected, 
whereas the HBM2 value is an intervention level. The (HBM I) for the sum of DEHP 
metabolites in urine is set for children (6-13 y) at 500 µg/l, for women in childbearing 
age 300 µg/l, and for the rest 750 µg/l [47]. The German Environmental Surveys 
(GerES) IV, a representative study, showed that 1.5 % of the investigated children 
exceed the HBM I value [46]. Additionally, GerES indicated that children have up to 
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four fold higher urinary phthalate metabolite levels than adults. The study also shows 
that the concentration levels decreased by increasing age [46]. 
Table 2 gives an overview of the urinary phthalate metabolite concentration of 
several biomonitoring studies conducted on children. In nearly all urine samples the 
phthalate metabolites were detectable [42]. Moreover, it shows that highest 
concentrations were observed for DEHP metabolites, followed by DnBP and DINP 
metabolites [46]. 
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Table 2. Phthalate metabolite concentration in urine [µg/l] 
Source MEHP 5oxo-MEHP 5OH MEHP 5cx-MEPP MnBP 
 MED Min-Max 95thP. MED Min-Max 95thP MED Min-Max 95thP MED Min-Max 95thP MED Min-Max 95thP 
Fromme et al, 2013 
n=663 [47] 
   17.9 0.8-168 58.2 16.5 0.8-225 60.2    32.4 2.3-221 124 
Langer et al, 2014 
n=441 [48] 
4.7 - 14.6 17.6 - 71.3 33.2 - 115.9 34.5 - 135.8 80.1 - 242.7 
Becker et al, 2004 
n=254 [49] 
7.18 0.74-223 29.7 97.7 <0.5-
1420 
139 52.1 1.86-2590 188 - - - - - - 
Koch et al. 2007 
n=239 [50] 
- - - - - - - - - - - - 166 15.5-3193 624 
Koch et al. 2003 
n=85 [51] 
10.3 <LOQ-
177 
37.9 36.5 0.5-544 156 46.8 0.5-818 224 - - - - - - 
Kasper-Sonnenberg 
et al. 2012 n=104 
[52] 
4.0 <LOQ-
27.7 
17.1 26.4 1.9-135 88.8 31 1.6-163 88.2 42.1 7.3-259 127 54.2 2.0-274 148 
Becker et al. 2009 
n=599 [46] 
6.7 <LOD-
319 
25.1 36.3 <LOD-
2490 
123 46 <LOD-3640 164 61.4 <LOD-
4490 
209 93.4 <LOD-
1090 
310 
Larsson et al. 2017 
n=113 [53] 
1.5 <LOD-11 5.6 12 1.5-82 37 17 1.8-133 56 16 2.4-100 52 54 3.9-327 141 
 MINP 7oxo MINP 7OH-MINP 7cx-MINP MBzP 
 MED Min-Max 95thP MED Min-Max 95thP MED Min-Max 95thP MED Min-Max 95thP MED Min-Max 95thP 
Fromme et al, 2013 
n=663 [47] 
- - - 4.6 0.2-486 29.9       11.6 0.8-311 80.7 
Langer et al. 2014 
n=441 [48] 
- - -          13 - 74.1 
Becker et al, 2004 
n=254 [49] 
- - -          - - - 
Koch et al. 2007 
n=239 [50] 
- - -          18.8 0.93-744 123 
Koch et al. 2003 
n=85 [51] 
- - -          21 1.2-268 146 
Kasper-Sonnenberg 
et al. 2012 n=105 
[52] 
- - -          11.7 0.5-368 62.9 
Becker et al. 2009 
n=599 [46] 
- - - 5.4 <LOD-
86.7 
28.9 11 <LOD-198 50.6 12.7 <LOD-
195 
58.9 18.1 <LOD-468 76.2 
Larsson et al. 2017 
n=113 [54] 
- - - 5.6 0.7-453 35 12 1.3-1100 93 17 1.7-2300 128 8.6 1-95 45 
All studies collected morning urine, except of Fromme et al.[47] and Larsson et al.[54] (spot urine samples); all urine samples were collected from children, MED: 
Median, Min-Max: minimum to maximum, 95th P.: 95th Percentile. 
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1I1I5 Short description of certain phthalates  
According to the Annex XVII to Regulation (EC) No 1907/2006 of the European 
Parliament and of the Council, toys which contains DEHP, BBzP or DnBP in a 
concentration greater than 0.1% by weight of plastics is not allowed to be placed on 
the EU market. DINP is forbidden to have higher concentration of 0.01% per weight 
in toys and childcare articles [14]. BBzP, DEHP and DnBP are also classified as 
substances of very high concern and are listed in REACH [54].  
 
1I1I5I1 Butyl benzyl phthalate (BBzP) 
Butyl benzyl phthalate is produced by esterification of phthalic anhydride. The 
resulting monobutyl ester of the phthalic acid reacts with benzyl chloride to form 
BBzP. The physicochemical properties of BBzP are described in Table 3. From 1994-
1997 36,000 tons p.a. of BBzP were produced and used within the European Union. 
The use and production of BBzP has decreased since 2004 (19,500 tons p.a.), 
because it was classified as toxic, possibly causing harm to unborn children (R61), 
risking impaired fertility (R62) and effecting the environment negatively, especially 
aquatic organisms (R50-53). According to Directive 76/769/EEC, the marketing and 
use of BBzP and preparations containing BBzP intended for consumer use is 
prohibited, which means it is banned in cosmetic products, toys and childcare articles 
[55]. BBzP is mainly used as a plasticizer in PVC products, especially in flooring. 
Besides PVC, sealants, adhesives, paints, ink and lacquers contain BBzP [56].  
Table 3. Physicochemical characteristics of BBzP [56] 
IUPAC Name Benzyl butyl phthalate 
CAS Number 85-68-7 
Molecular formula  C19H2004 
Molecular weight 312.35 g/mol 
Physico-chemical properties Physical state: Clear oily liquid 
 melting point < -35°C 
 boiling point: 370°C at 10.10 hPA 
 relative density 1.116g/cm³ at 25°C 
 vapor pressure 0.00112 Pa 
 water solubility 2.8 mg/l at 20-25°C 
 Partition coefficient n-octanol/water  4.84 
Structural formula 
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Toxicokinetics of BBzP  
For the general population, the most probable means of BBzP exposure are 
ingestion and inhalation of indoor air. The absorbed BBzP is metabolized to mono 
butyl phthalate (MnBP) and mono benzyl phthalate (MBzP) in the gut wall and/or in 
the liver (Fig. 2). In rats, where most toxicokinetic studies have been made, the ratio 
of MnBP and MBzP is 3:1. On the contrary, in humans, the main metabolite and 
therefore an adequate biomarker seems to be MBzP. Based on limited data, the half- 
life time seems to be less than 24 hours [56].  
 
Figure 2. Schematic view of the Metabolism of BBzP [56]. BBzP: Benzylbutyl phthatale, MnBP: mono-
n-butyl phthalate, MBzP: mono-benzyl phthalate. The framed metabolite MBzP is qualified as a 
biomarker. 
 
Health effects 
This phthalate has a low acute toxcixity (oral LD 50 20,400 mg/kg). Repeated dose 
toxicity studies (mainly in rats) resulted in decreased body weight gain, negative 
effects to organs as liver, kidney, spleen and pancreas and male genital tract as 
testes, epididymis and prostate. Besides altering the semen parameters (already 
mentioned above), BBzP is inversely related to the anogenital index (AGI). Boys with 
a high prenatal maternal urinary MBzP concentration had a higher probability of a 
lower AGI [56].  
BBzP is associated with rhinitis, eczema (atopic dermatitis), allergy and a higher risk 
of asthma especially for children (reviewed by Bekö [57]). In an epidemiological study 
conducted by Bornehag et al. [45], a relationship between the BBzP concentration in 
children’s bedroom dust and diagnosed rhinitis or eczema was determined. Several 
in vivo and in vitro studies indicate a weak estrogenic as well as an anti-androgen-
like activity after a high dose of BBzP [56].  
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1I1I5I2 Di-n-butyl phthalate (DnBP) 
DnBP production occurs through the reaction of phthalic anhydride with n-butanol in 
the presence of concentrated sulphuric acid (catalysator). DnBP is used as a gelling 
aid (for cellulose ether, polyvinyl acetate dispersion), a lubricant (textile manufacture), 
an antifoam agent or a solvent (oil-soluble dyes, insecticides, peroxides etc.). The 
enteric coating material in medications or food supplements also contains DnBP. 
Formerly, DnBP was added to cosmetic products to enhance durability and 
smoothness but since April 2005, it is no longer available on the European market. 
However, this plasticizer can be found in a wide range of end products like textiles, 
coatings and the primary packaging of medicines [58, 59].  
Based on the European restriction, the production and use of DnBP has decreased 
from 26,000 tons in 1998 to 10,000 tons in 2007. The physicochemical 
characterization of DnBP is given in Table 4.  
Table 4. Physicochemical characteristics of DnBP  
IUPAC Name 1,2-Benzendicarboxylic acid dibutyl ester 
CAS Number 84-74-2 
Molecular formula  C16H22O4 
Molecular weight 278.34 g/mol 
Physico-chemical properties Physical state: Oily liquid 
 melting point -69°C 
 boiling point: 340°C at 1,013hPa 
 relative density 1.045g/cm³ at 20°C 
 vapor pressure 9.7±3.3x10-5 hPa at 25°C 
 water solubility 10 mg/l at 20°C 
 Partition coefficient n-octanol/water  Log Kow 4.75 
Structural formula 
 
 
Toxicokinetics of DnBP 
The exposure to DnBP occurs mainly through oral uptake, where it is rapidly 
absorbed and mainly excreted in urine within 48 hours. Fecal excretion is very low 
and negligible. Compared to oral uptake, dermal absorption is with 2.4 µg/cm²/hour 
relatively slow. After dermal exposure to rats, 60 % of the dose was excreted within 7 
days [60]. 
The metabolism of DnBP was investigated by Koch et al. [59]. Di-n-butyl phthalate is 
metabolized to mono-n-butyl phthalate (MnBP) and then further oxidized to its 
metabolites 3OH–mono-n-butyl-phthalate (3OH-MnBP) and 4OH-mono-n-butyl-
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phthalate (4OH-MnBP). The latter is then metabolized to 3-carboxy-mono-
propylphthalate (MCPP) (as shown in Figure 3). In this study, it was postulated that 
84% of the applied DnBP doses was excreted as the primary metabolite MnBP, with 
a half-life time of 2.6 hours. Therefore MnBP is an appropriate biomarker for 
biomonitoring studies.  
 
Figure 3. Schematic view of the DnBP metabolism (according to Koch et al. [59]). DnBP: di-n-
butylphthalate; MnBP: mono-n-butylphthalate; 3OH-MnBP: 3OH-mono-n-butylphthalate; 4OH-MnBP: 
4OH-mono-n-butylphthalate; MCPP: 3carboxy-mono-propylphthalate; the framed metabolite are 
qualified biomarkers. 
 
Health Effects  
DnBP is classified as reprotoxic. DnBP seemed to have more of an anti-androgenic 
effect than estrogenic. Reproductive toxicity studies in male rats showed increased 
incidence of undescended testes, hypospadias, malformation of reproductive organs 
and nipple retention. The underlying mechanism might be a decrease in the fetal 
testicular testosterone production in Leydig cells. DnBP is associated with sperm 
motility and weak evidence of an altered morphology was found [39]. In a Chinese 
case control study, a relationship between a higher meconium DnBP metabolite level 
and lower birth weight in infants was found [17]. The No observed adverse effect 
level (NOAEL) ranges between 20 to 50 mg/kg body weight per day [61].  
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1I1I5I3 Bis (2-ethylhexyl) phthalate (DEHP) 
The production of DEHP occurs through the esterification of phthalic anhydride with 
2-ethyl-hexanol [15]. DEHP is mainly used as plasticizers in polymer products, 
especially in flexible PVC (up to 30 % DEHP content), which is used in many different 
products as toys, building material (flooring), cables and medical products (tubes, 
blood bags, etc.). Besides PVC, it is also used in polymer and non-polymer 
formulations and products like sealants, paints lacquers or ceramics. In 1997 the 
volume of production of DEHP was estimated to be 595,000 tons p.a. in Western 
Europe. Since 2004 the use of DEHP has decreased to 221,000 tons p.a., while the 
production and use of phthalates to substitute DEHP, DINP and DIDP has increased. 
Based on the fact that DEHP slowly migrates from polymer products during their 
complete lifetime, both humans and the environment are constantly exposed to 
DEHP [62]. Its physicochemical properties are given in Table 5.  
According to Annex I of Council Directive 67/548/EEC [63], DEHP is classified as 
toxic to reproduction (Category 2; R60-61).  
Table 5. Physicochemical characteristics of DEHP 
IUPAC Name Bis (2-ethylhexyl) phthalate  
CAS Number 117-81-7 
Molecular formular  C24H38O4 
Molecular weight 390.56 g/mol 
Physico-chemical properties Physical state: Colourless oily liquid 
 melting point -55°C 
 boiling point: 385°C at 1013hPa 
 relative density 0.98 g/cm³ at 20°C 
 vapor pressure 0.000034 PA at 20°C 
 water solubility 3 µg/l at 20°C 
 Partition coefficient n-octanol/water  7.5 
Structural formula 
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Toxicokinetics of DEHP  
The DEHP exposure occurs through oral, inhalation, dermal or intravenous 
pathways. The main exposure source is intake of food which is DEHP-contaminated 
either by general environmental pollution or by contact with DEHP containing 
materials, DEHP handling and preparation processes.  
After oral uptake, DEHP is rapidly absorbed and metabolized in the gastrointestinal 
tract. DEHP is quickly hydrolyzed to mono (2-ethylhexyl) phthalate (MEHP -primary 
metabolite) and 2-eythalhexanol (2-EH) by lipases in the small intestine. In the liver, 
MEHP is further modified by several side-chain oxidation and hydroxylation reactions. 
A toxicokinetic study conducted by Koch et al.[13] showed that after 24 hours 67 % of 
the applied DEHP dose was excreted as five of the major metabolites: 2-ethyl-5-
hydroxy-hexylphthalate (5OH-MEHP; 23.3 %), 2-ethyl-5-carboxy-pentylphthalate 
(5cx-MEPP; 18.5 %), 2-ethyl-5-oxy-hexylphthalate (5 oxo-MEHP; 15 %), mono (2-
ethylhexyl) phthalate (MEHP; 5.9 %) and 2-(carboxymethyl)-hexylphthalate (2cx-
MMHP; 4.2 %). On the second day only 3.8 % of DEHP was excreted as 2cx-MMHP 
(1.6 %), 5cx-MEPP (1.2 %), 5OH-MEHP (0.6 %) and 5 oxo-MEHP (0.4 %). Further it 
was shown that the secondary metabolites have longer elimination half-life time and 
a later concentration maximum as the monoester MEHP. The long half-life 
elimination qualifies 5cx-MEPP and 2cx-MMHP (12-15 hours and 24 hours) as 
biomarkers to measure time-weighted exposure, while 5OH-MEHP and 5oxo-MEHP 
(10 hours) represent more a short-term exposure to DEHP. A dose dependency in 
metabolism and excretion was not observed. A graphic scheme is shown in Figure 4.  
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Figure 4. Schematic view of the DEHP metabolism (according to Koch et al. [64]), the framed 
metabolites are qualified biomarkers. 
 
Health effects 
The acute toxicity of DEHP is very low. The oral LD50 ranged between >20,000 mg/kg 
b.w. (rats) and > 10,000 mg/kg b.w. (mice). DEHP is not reported to be mutagenic or 
carcinogenic. In several repeat dose toxicity studies (orally administered), it was 
shown that DEHP induces toxicity to testes and kidneys. In rodent studies, DEHP 
affected fertility and reproduction in both sexes and also influenced development in 
the offspring. Further, it was shown that DEHP-induced testicular toxicity causes less 
harm to a sexually mature animal than to a developing and prepubertal animal. The 
primary metabolite (MEHP) is suspected to be the active metabolite, which affects 
testes and reproduction. The main target of DEHP (MEHP induced testicular toxicity) 
are the Sertoli cells and Leydig cells. Further, it decreases the capacity of the follicle 
stimulating hormone (FSH) in Sertoli cells, zinc and the testosterone levels in the 
testes. Low zinc levels in testes enhance the susceptibility to gonadotoxic effects in 
male rodents. Based on limited human data, the observed NOAEL for testicular 
effects of 4.8 mg/kg/d in animal studies was considered to be relevant for humans as 
well. Besides testicular effects, some research indicates that oral dosing of DEHP 
cause hypo-oestrogenic anovulatory and polycystic ovaries in adult female rats. An 
alteration in the oestrus cycle with resulting changed testosterone and oestradiol 
concentration in ovary cells was observed after DEHP administration to female rats. 
Developmental toxicity has been observed in several studies, the rats male pups 
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showed DEHP-induced malformations, e.g. demasculinisation or reduced AGD by 
inhibiting fetal testosterone production. In vitro as well as in vivo studies indicate that 
DEHP interferes with the endocrine function and might have antiandrogen effects. 
Therefore DEHP can influence sexual differentiation [15].  
Besides reprotoxicity, DEHP might influence the thyroid hormone system. An inverse 
association between MEHP and free T4 and total T3 was observed. More data are 
needed to determine the importance of such an association [43].  
From an epidemiological point of view, a significant association was found with a high 
concentration of DEHP in children’s bedroom dust and diagnosed asthma [45].  
 
1I1I5I4 Diisononyl phthalate (DINP)  
There are three different kinds of DINP, which are also produced in different ways. 
The first DINP (CAS 68515-48-0) is made by the “polygas” process, the second one 
(CAS 28553-12-0) is n-butene based and the third one (CAS 28552-12-0) is 
produced n- and iso-butene based. DINP 1 is a mix of esters of the o-phthalic acid 
with C8-C10 alkyl alcohols of different chain lengths and branching distribution, 
whereas DINP 2 has only isomeric C9 alcohols in the ester chain. Since 1995, the 
production of DINP 3 (CAS 28552-12-0) has stopped. Based on the different 
chemical structures, the three DINPs may have different physicochemical and 
toxicological characteristics (the general ones are shown in Table 6) [65, 66].  
In 1994, 107,200 t of DINP were produced in the European Union. Because of low 
toxicity, DINP is replacing DEHP and therefore the production of DINP has increased 
in the last two decades. Ninety-five% of the DINP produced is used as a plasticizer in 
PVC products, the other five % are mainly used in polymer products (e.g. rubbers). 
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Table 6. Physicochemical characteristics of DINP [67] 
IUPAC Name 1,2-Benzenedicarboxylic acid, di-C8-10 branched alkyl esters, C9 
rich and di-“isononyl”phthalate 
CAS Number 685515-48-0 and 28553-12-0 
Molecular formula  C8+2xH6+4xO4 with x=8 to 10 (x=9 as main constitution) → C26H42O4 
Molecular weight 420.6 (average) g/mol 
Physio-chemical properties Physical state: Oily viscous liquid 
 melting point Ca. -50°C 
 boiling point: >400°C 
 relative density ca.0.975 at 20°C 
 vapor pressure 6*10-5 Pa at 20°C 
 water solubility 0.6 µg/l at 20°C 
 Partition coefficient n-octanol/water  8.8 
Structural formula 
[67] 
[68] 
 
Toxicokinetics of DINP 
The routes of DINP exposure are mainly oral through consumer products, food or 
toys. The dermal or inhalation pathway is very limited. The dermal uptake of DINP is 
very slow (4 % of the dose within 7 days).  
After the oral uptake, DINP is rapidly hydrolyzed to MINP in the gastro-intestinal tract 
(GIT) and then absorbed. MINP undergoes an oxidative metabolism by the ω-
oxidation (oxidation of the terminal carbon atom of the side chain) or ω-1 oxidation 
(oxidation of the penultimate carbon atom of the side chain) pathway to form 
secondary metabolites with hydroxyl-, oxo- and carboxyl- functional groups (7OH-
MINP, 7oxo-MINP and 7cx-MINP) [12] (see Figure 5). The distribution compartments 
are the liver, kidney and blood but DINP does not accumulate in the body. In a 
toxicokinetic study conducted by Koch et al. [69], 43.6 % of the applied dose was 
excreted mainly as OH-MINP (20.2 %), carboxy-MINP (10.7 %), oxo-MINP (10.6 %) 
and MINP (2.1 %) within 48 hours. The estimated half-life time is between three to 
five hours within the first elimination phase of 24 hours post dose. In rodents, a 
limited absorption in a high dose range was observed [11].  
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Figure 5. Schematic view of the DINP metabolism (4 methyl-octyl side chain) [69], DINP: Di-
isnonylphthalate, MINP: mono (4 methyloctyl) phthalate, 7OH-MINP: -mono-(4-methyl-7-hydroxyoctyl) 
phthalate (7OH-MMeOP); 7-oxo-MINP: mono (4-methyl-7oxooctyl) phthalate (7oxo-MMeOP); 7cx-
MINP: mono (4-methyl-7-carboxy-heptyl) phthalate (7-carboxy-MMeHP). 
 
 
Health effects 
DINP has a low acute toxicity and showed no irritant effects on skin, eyes or the 
respiratory system. Neither mutagenic nor carcinogenic effects were observed. In 
repeated-dose toxicity studies in rats or mice, no effects on testes weight, estrogen 
activity and developmental malformation were observed, but biochemical changes in 
liver (increased asparate-aminotransferase (AST) and alanine aminotransferase 
(ALT) and an increased liver weight. Only one study showed a reduced mice testis 
weight after a high dose of DINP (5.7 mg/kg/d). The EU did not classify DINP[14].  
 
1I2 Dust 
In industrial countries, humans spend 60 to 90% of their time indoors, either at home, 
in offices or in transportation facilities. The indoor environment is a significant source 
of pollutants which are found in various products like detergents, furniture, flooring 
and wall covering material. In addition, indoor activities such as smoking and cooking 
as well as the frequency of air exchange can influence the level of pollutants in the 
indoor environment. The greater amount of time spent indoors, limited room 
ventilation, and slower chemical degradation rates lead to higher indoor pollutant 
exposure compared to outdoors. Analyzing indoor dust can give information about 
the presence of, and exposure to, pollutants in indoor environments. House dust is 
linked to adverse health effects like asthma and allergies because it is a transport 
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medium for allergens, heavy metals, semi- and non-volatile chemical substances, 
e.g. phthalates or polybrominated diphenyl ethers [70-74]. Dust is characterized as 
indoor particles that have settled on the surface of objects, as well as floors and 
carpeting. It also includes soil particles or other organic matter that has been tracked 
or blown into the indoor environment from outside [75]. Dust composition differs not 
only between indoors and outdoors, it also varies between the kitchen, living room 
and bathroom of a dwelling [76]. Hawley et al. [25] estimated that the average 
amount of dust on an indoor surface is approximately 560 mg/m². Dust contains 
human and animal skin fragments and hair, paper fibers, glass wool, textile fibers, 
organic, inorganic and metal particles, in descending order [73]. The particle size of 
dust caused by abrasion from furniture and everyday objects ranges from 0.001 to 1 
mm [77]. 
 
1I2I1 Phthalates in dust 
As a consequence of their ubiquitous usage, phthalates are one of the most 
frequently occurring compounds in house dust. Phthalates are released as vapor 
from the flooring material containing PVC which is then absorbed by particles in 
indoor air.  
Phthalates like DEP, DnBP and DiBP tend to exist as gases and are therefore more 
frequently found in indoor air, whereas DEHP, DINP and BBzP, being less volatile, 
are more common in house dust [78]. Based on the lack of degradation or dissipation 
of the organic pollutants which are bound to dust, organic pollutants have a high 
exposure potential [79]. The composition of house dust is non-homogeneous and the 
phthalate concentrations are highly variable. It has been shown that phthalate 
accumulations strongly depend on particle size distribution in house dust [30]. Wang 
et al. [80] investigated the accumulation rate of phthalates in different particle sizes < 
63 µm, 63 - 100 µm, 100 - 280 µm and 280 - 2,000 µm; the highest rates were found 
at < 63 µm and 63 - 100 µm. Bioaccessibility decreased by increasing particle size. 
Particles with <63 µm are associated with a higher health risk for humans than 
particles with diameter of 280 - 2000 µm. Furthermore, it was shown that particles < 
250 µm have the highest capacity to be collected by the human hand [29].  
Table 7 gives an overview over the phthalate concentration in house dust.  
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Bornehag et al. [81] measured the phthalate content in dust in relation to building 
types in 390 homes in Sweden. The phthalate most frequently and with the highest 
levels of concentration detected in dust was DEHP, followed by DnBP and BBzP. In 
this study it was shown that flooring materials influence the phthalate concentration. 
Apartments with PVC flooring have a higher DEHP and BBzP content in dust 
compared to apartments with no PVC. In addition to PVC, there are other sources 
which influence the DEHP background concentration because the average DEHP 
content in dust in PVC flooring apartments was found to be around 0.7 mg/g, 
whereas in dwellings containing no PVC, the DEHP content was 0.55 mg/g. In 
contrast, this effect was not observed for BBzP. In other studies published by 
Fromme et al. [47] did not observe this effect. Hwang et al. [79] investigated the 
exposure of endocrine disrupting chemicals, like phthalates, polybrominated diphenyl 
ethers and polychlorinated biphenyls in dust samples from 10 apartments and one 
community hall in California, USA. This study revealed that DEHP was the most 
frequently detected pollutant in all dust samples and its concentration was 104-7630 
µg/g which is two to six times higher compared to other pollutants. 
DnBP is associated with compressed wood floors because DnBP is often used as a 
gloss agent in plastic additives or paint for such floors. Furthermore, an association 
between the frequency of cleaning the floor and DnBP was found, based on the fact 
that DnBP is often a component in cleaning products [82]. 
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Table 7. Phthalate concentration in dust [mg/kg] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All dust samples were sieved <63µm except of Blanchard et.al. (100µm), Guo et al. (2mm) from vacuum cleaning bags; Fromme et al. [47], Langer et al.[83], 
Bamai et al [82] Larsson et al. [53] used filters. 
 
Source BBzP DEHP DnBP DINP 
 MED Min-Max 95th P MED Min-Max 95th P MED Min-Max 95th P MED Min-Max 95th P 
Fromme et al,2013  
n= 63 [47] 
6 0.1-348 93 888 99-10086 7616 21 2-266 95 302 30-7091 2955 
Bamai et al 2013 
n=128 [82] 
2 1.0-139  1110 213-7090 - 16.6 2.0-1670 - 139 11.9-2100 - 
Wang et al.,2013 
(Hong Kong) n=20, 
[80] 
4.28 0.61-
81.9 
- 528 96.8-2190 - 4.8 0.25-17.4 - - - - 
Blanchard et al. 
2014, n= 30 [78] 
8.5 - - 289 - - 11.9 - - 130 - - 
Langer et al. 2010 
n=497, [83] 
3.7 0.7-285 - 210 12.7-6611 - 15 0.18-253 - - - - 
Guo et al. 2011  
(China), n=75 [84] 
0.2 n.g-12.0 - 228 9.9-8400 - 20.1 1.5-1160 - - - - 
Guo et al. 2011 
(USA) n=33, [83] 
21.2 3.6-393 - 304 37.2-9650 - 13.1 4.5-94.5 - - - - 
Larsson et al. 
2017,(Sweden) 
n=100,[53] 
8.7 - 110 290 - 1900 21 - 140 380 - 3400 
Abb et al. 2009 
(Germany) n=30 
[72]  
15.2 - - 604 - - 29 - - 129 - - 
 31 
 
1I2I2 Exposure through dust 
House dust is suspected to be an important exposure pathway to environmental 
pollutants. Especially young children ingest a high amount of dust via a high hand to 
mouth or object to mouth frequency. Because of their lower body weight, children 
have a relative high dust uptake, which can cause a potential health risk [85]. 
In general there are three different approaches to estimate the exposure through 
dust.  
1. Tracer element methodology: tracer as heavy metals as e.g. lead in dust, are 
used to quantify the amount of dust intake. Ideally the tracer does not be 
metabolized and excreted via feces or urine and it’s only found in high 
concentration in dust. Estimated dust uptake ranged between 26 - 470 mg/d. 
2.  Biokinetic model comparison methodology: This method is used to compare 
biomarkers in urine or blood from the toxicant with exposure pathways as diet, 
air, dust and soil. With data from the literature the dust uptake is expected to 
be 100 mg/d. 
3. Active pattern methodology: It is a combination of analyzing the frequencies of 
hand to mouth and object mouth activity and time spend outdoor and indoors. 
Estimated dust and soil uptake of 10-1000 mg/d [85].  
 
Based on the literature and model data’s, the US-EPA estimated that the average 
uptake of dust ranged between 30 to 60 mg/d. Infants (six weeks to < one year) and 
adults have an unintended oral uptake of 30 mg, while toddler and children (one year 
to six years and six to twenty-one years) ingest 60 mg dust per day. For the age 
group three to six years, an upper percentile of 100 mg dust per day was defined [75, 
85].  
 
The Danish authorities [58] predicted the DnBP ingestion on a daily basis to be 
around 2.3 µg/kg b.w. in summer (50 mg of dust ingestion/day) and 4.1 µg/kg b.w. in 
winter (100 mg of dust per day).  
Depending of the phthalate and its concentration in dust, oral exposure ranges 
between 0.5-21 µg/kg per day (details are shown in Table 8) [86]. 
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Table 8. Phthalate intake through dust ingestion (reviewed by Oomen etal. [86]) 
Phthalate Mean ingestion rate [µg/kg/d] Maximum ingestion rate [µg/kg/d] 
 Adult Child Adult Child 
BBzP 0.23 2.1 32 304 
DEHP 2.3 21 29 270 
DIDP 0.052 0.49 0.05 0.49 
DINP 0.12 1.2 0.12 1.2 
DiBP 0.060 0.56 0.06 0.56 
DnBP 0.16 1.5 3.9 36 
 
Kang et al. [87] investigated the oral bioaccessibility1 in dust by an in vitro digestion 
test. It was shown that the bioaccessibility of DEHP, BBzP and DnBP ranged 
between 10-15 %. By simulating the gastric and intestinal conditions, Wang et al. [80] 
published lower bioaccessibility levels as Kang et al. (2.2 - 12.6 % for DiBP, BBzP, 
DEHP, DIDP). Additionally, a higher bioaccessibility of DMP (15.5 %) at 63 µm dust 
size fraction compared to 0.14 % at 280 - 2000 µm was observed.  
In a bioavailability study conducted by Freeman et al. [90], it was shown that arsenic 
in dust and soil is 3.5 to 5 times less bioavailable than arsenic solved in a solution. It 
indicates that there is an association with the n-octanol/water coefficient (KOW) and 
bioavailability or bioaccessibility. The higher the KOW value, the lower the oral 
bioaccessibility [91]. 
 
Several biomonitoring studies investigated the correlation between children phthalate 
body burden and the phthalate concentration in dust. Fromme et al. [47] measured 
the phthalate concentration in air and dust from German day care centers and 
phthalate metabolite concentration in 663 samples of children’s urine after attending 
the investigated day care centers. A significant correlation of phthalates 
concentration in dust and concentrations of metabolites in urine was only found at the 
bivariate analysis level. Another study conducted by Fromme et al. [92] reported the 
occurrence of phthalates in indoor air and dust from 133 apartments and daycare 
centers in Berlin, Germany.  
                                            
1 Bioaccessability is the amount of a tracer that is soluble or accessible in the gastrointestinal 
environment but not necessarily available for assimilation, whereas bioavailabiliy means that, in 
addition to being accessible in the gastrointestinal environment, the ingested contaminant can reach 
the blood circulation and exert toxic effects.  88. Turner, A., Bioaccessibility of Trace Metals in 
Household Dust A2 - Nriagu, J.O, in Encyclopedia of Environmental Health 2011, Elsevier: Burlington. 
p. 317-322. 89. Yuswir, N.S., et al., Bioavailability of heavy metals using in vitro digestion model: a 
state of present knowledge. Rev Environ Health, 2013. 28(4): p. 181-7. 
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They found that an unintended intake of dust (assumption of 100 mg dust per day) of 
young children could contribute 25 % of the total DEHP body burden.  
In a comparative assessment of phthalate exposure through house dust in China and 
the USA conducted by Gou et al. [84], the results indicated that house dust intake 
accounts for less than 2.2 % of DiBP and DnBP and two to five percent of DEHP 
intake in China, whereas the intake rates in the USA were higher (1 – 16 % for DiBP 
and DnBP, 3 – 21 % for BBzP and 10 – 58 % for DEHP).  
Langer et al. [48] observed significant correlations between DEP, DnBP, DiBP and 
BBzP in dust and their metabolites in children’s urine. For DEHP, there was no 
significant correlation with its observed metabolites.  
 
It is still unclear how much the dust uptake contributes to phthalate exposure. The 
knowledge of bioavailability of phthalates in dust is very limited. Therefore the 
bioavailability of dust is often assumed to be 100 %. However, by this hypothesis, 
children could exceed the TDI through dust ingestion, but the results of human 
biomonitoring studies indicated that this is normally not the case.  
 
1I3 The aim of the study  
This study is conducted to examine the bioavailability of phthalates in house dust 
after oral administration to the model organism, the pig. In this study, we focused on 
phthalates which are highly present in dust and where biomonitoring data showed 
that the human is highly exposed to.  
The aim of the study is to: 
 Determine if dust is a potential source of phthalate exposure, especially for 
toddlers and infants; 
 Investigate if the bioavailability of plasticizer differs in house dust and food 
matrices. 
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2I Material and Methods  
In this in vivo bioavailability study of certain phthalates2 in house dust, eight piglets 
(5-6 weeks old, male, 11-14 kg b.w.; one dropout) received five different dust 
samples and one food sample. The experiment took place from the 5th of October to 
the 15th of November 2015 at the Federal Institute for Risk Assessment in Berlin, 
Germany and was approved by the Regional Office of Health and Social Affairs 
(LAGeSo). The written approval for this animal experiment (Reg 0272/13) and the 
experiment plan (Table A1.) appears in the appendix.  
 
2I1 Study design and sampling  
The dust samples, as well as the food sample, were orally administered to the pigs in 
their morning feeding. The amount of dust given ranged from 432 mg to 832 mg 
(Table 9). 
The food sample consisted of 25 µl of the 1 % ethanol-phthalate mixture. A stock 
solution for each phthalate was made (e.g.10 ml ethanol with 10.7 mg BBzP; 501.2 
mg DEHP, 52.5 mg DINP, and 10.4 mg DnBP). Afterwards 23 µl of the BBzP stock 
solution, 2504.4 µl of the DEHP stock solution, 863.3 µl of the DINP stock solution 
and 44 µl of the DnBP stock solution were diluted in 25 ml ethanol. Table 10 gives an 
overview of the phthalates content in the dust samples. The chemicals which were 
used for the solution are listed in Table A2 in the appendix. The given dose was 
adjusted to the levels of the tolerable daily intake (TDI) of DEHP (50 µg/kg b.w.).  
Table 9: Administered amount of dust [mg] 
mg  Dust A Dust B Dust C Dust D Dust E 
Pig 1 592.21 443.32 553.69 650.41 832.00 
Pig 2 600.9 457.53 535.31 670.39 825.31 
Pig 3 560.91 456.36 544.86 691.00 753.06 
Pig 4 565.07 445.57 620.32 684.67 735.25 
Pig 5 569.09 451.38 550.34 667.06 763.00 
Pig 6 566.42 478.53 528.76 654.67 786.57 
Pig 7 592.58 432.34 541.02 662.76 742.20 
                                            
2  Butylbenzyl phthalate (BBzP), Di-n-butylphthalate (DnBP), Diethylhexylphthalte (DEHP) and 
Diisononyl phthalate (DiNP)  
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Table 10. Overview of phthalate concentration in the administered dust and food sample 
[mg/kg] Dust A Dust B Dust C Dust D Dust E Food 
BBzP 30 180 50 4 20 19 
DEHP 6900 8700 7000 5800 4800 2500 
DnBP 70 50 240 50 10 31 
DINP 1100 470 1700 2100 4300 857 
 
For an eventual background exposure, a urine sample (control urine) was collected 
before the dust/food sample was given. After the oral administration, the urine was 
collected over a period of 38 h. The volume of the collected urine was noted and a 
maximum of 100 ml of the excreted sample was refilled in a polyethylene cup and 
stored at -20 °C until further analysis and measurement.  
To avoid any bias, the order of the dust sample varied between the piglets. Also, 
before, during and after an experiment, to the extent possible, any contact with 
phthalates was avoided. After each single experiment, a three day washout period 
was followed to avoid any influence from the previous experiment. Figure 6 shows 
the experiment setting and a detailed description of the single experiment procedure 
is given in Table 11.  
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Figure 6. Metabolite cages with urine collecting vessels. 
 
Table 11. Detailed schedule of a single oral experiment 
Day Sample no Time  
Day 1  22:00 Piglets were put in the metabolite cages 
Day 2 1 06:00 Urine sampling and sample administration 
Day 2 2 07:00 Urine sampling 
Day 2 3 08:00 Urine sampling 
Day 2 4 09:00 Urine sampling 
Day 2 5 10:00 Urine sampling 
Day 2 6 11:00 Urine sampling 
Day 2 7 12:00 Urine sampling 
Day 2 8 13:00 Urine sampling 
Day 2 9 14:00 Urine sampling 
Day 2 10 15:00 Urine sampling 
Day 2 11 16:00 Urine sampling 
Day 2 12 17:00 Urine sampling 
Day 2 13 18:00 Urine sampling 
Day 2 14 20:00 Urine sampling 
Day 2 15  22:00 Urine sampling 
Day 3 16 06:00 Urine sampling 
Day 3 17 10:00 Urine sampling 
Day 3 18 14:00 Urine sampling 
Day 3 19 18:00 Urine sampling 
 37 
 
Day 3 20 20:00 Urine sampling 
Day 3  20:00 Piglets left the metabolite cages 
 
2I2 Pig keeping 
 
The 6 week old piglets (Landschwein x Edelschwein, F1 generation x JSR Top Vital 
Pietrein) had access to water ad libitum and received 900 g of cooked potatoes 
(class: princess, from a local farmer, Germany) twice a day (6 am and 4 pm). During 
their three day wash-out period, 250 ml of Fresubin© (Fresenius Kabi, Germany) was 
added to their morning feed ration to avoid a nutrition deficiency. Two piglets shared 
a pigpen, the floor of which was covered with straw. The temperature in the daylight 
pigpen was regulated at 26 °C. The piglets were weighed regularly to verify their 
condition. During the total experiment period, they gained four to five kilograms each.  
 
 
2I3 Analytical methods 
2I3I1 Analysis of phthalates in dust  
The dust sample originated from another study “Phthalates in German daycare 
centers: Occurrence in air and dust and the excretions of their metabolites by 
Children (LUPE3)” and were collected in several day care centers in Bavaria, Berlin 
and North-Rhine-Westphalia between November 2011 and May 2012 [47]. The five 
dust samples with the highest levels of phthalates were chosen for this project. The 
dust3 from the vacuum bags of child daycare centers were sieved through a 63 µm 
sieve and stored in glass jars covered with aluminum foil. For analyzing the phthalate 
concentration, 100 - 150 mg of the sieved dust were distributed into glass vials and 
spiked with internal standard DMP-d4, DBP-d4, BBP-d4 and DEHP-d4. 
Subsequently, it was sonicated for 15 min and transferred to centrifuge tubes. The 
glass vials were washed with 5 ml MTBE and then centrifuged (3076 x g, 15 min, + 5 
°C). The supernatant was refilled in brown glass screw cap vials (PTFE-silicone 
washer) for 15 min (3076 x g +5°C) then subsequently decanted in brown glass 
                                            
3 The dust originated from the bag of the vacuum cleaner from the child day care center. Those dust samples 
gives a representative overview of the general indoor phthalate exposure in the child day care centers. 
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screw cap vials (PTFE-silicone-washer). For quality measurement, control blank 
samples were prepared. The samples were analyzed by a gas chromatographic 
system with a mass selective detector in electron impact (EI) mode (Shimadzu GC-
MS QP2010 with 30m/0.25mm ID/0.25 µm Phenomenex Zebron ZB-5 ms). The limit 
of detection (LOD) and limit of quantitation (LOQ) for DEHP was 0.3 ng/g and 1 ng/g, 
for DnBP 0.2 ng/g and 1 ng/g, for DINP 3 ng/g and 7 ng/g, and for BBzP 0.1 ng/g and 
1 ng/g [47]. 
 
2I3I2 Phthalate metabolite analysis in urine 
The phthalate metabolites were quantified with an accredited analytical method 
(QSP-O-1616-02) as previously published by Völkel et al. [93].  
 
Sample preparation 
200 µl of the thawed room temperature urine sample were mixed with 55 µl of 
ammonium acetate buffer (1M, pH 6.5, Riedl-de Haën), 10 ng of an internal standard 
mix (1 ng/µl), and 5 µl of β-glucuronidase (Type 2 H-2 from Helix promoatia, Sigma). 
For the enzymatic hydrolysis, the samples were placed in a thermomixer for 1.5h 
(500 l/min, 37 °C). After the enzymatic hydrolysis, 250 µl acetonitrile (LC-MS Grade, 
Fischer Chemicals) were added. The samples were centrifuged for 15 min at 20,800 
x g to eliminate potential depositions. The sample solution was then decanted in a 
vial and filled up with 480 µl of 0.5 % formic acid (Roth, Germany).  
For quality control, spiked samples consisted of 980 µl of control urine and 20 µl of 
native Standard mix. Two hundred µl of spiked urine were taken out and processed 
like the regular urine sample. In addition to the regular samples, the urine samples 
taken in the third and fourth hour after administration were diluted with purified water 
in a ratio of 1:10. The concentration values from diluted and undiluted samples were 
compared. Both values showed similar values. All samples were prepared as 
duplicates and each batch included a spiked urine sample (as well in duplicate) to 
control measurement quality.  
Analytical methods, quantitation and chemicals  
50 µl of the sample were injected into a high-performance liquid chromatography 
(HPLC) system (UlitMate 3000), using a column switching unit), where the separation 
occurred, which is coupled with an AB Sciex Q Trap 5500 tandem mass 
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spectrometer, where the mass detection was performed. The instrumental analytical 
method is listed in Table 12.  
Table 12 Detail description of the used phthalate LC-method 
Trap column 25 µm, 20x2.1mm ID (Oasis HLB, Waters Oasis) 
 Mobile phase  HPLC gradient water with 0.1% formic acid (Solvent A) 
&acentonitrile), with 0.1% formic acid (Solvent B) 
 Injection  50 µl 
 Time 0 - 2 min 2.1 - 16 min 16.1 - 20min 20.1 - 22 min 
 Flowrate 1ml 0 ml 1ml  1ml 
 Isocratic 
(Solvent B) 
10% 10% 100% 10% 
Analytical collumn  3µm, 150x3mm (Luna Phenyl-Hexyl, Phenomenex) 
 Mobile phase HPLC gradient water with 0.1% formic acid (Solvent A) 
&acentonitrile with 0.1% formic acid (Solvent B) 
 Time 0 - 2 min 2 - 13 min 13.1 - 20 min 20.1 - 22 min 
 Flowrate 0.4 ml 0.4 ml 0.4 ml 0.4 ml 
 Gradient 
(Solvent B) 
35%  35-65% 100% 35% 
At the quadruple mass spectrometer, the following settings were used to detect the 
investigated analytes: a negative ion mode with curtain gas (N2) 45 psi, nebulizer gas 
55 psi, turbo gas 60 psi, heated gas temperature 600 °C, ion spray voltage -4000 V, 
dwell time 30 ms. Data quantitation was set in the multiple reaction monitoring (MRM) 
mode. The settings for the qualifier and quantifier ions, as well as the list of reference 
and internal standards are shown in the appendix in Table A3 and Table A4.  
For quantification of the phthalate metabolites, a calibration curve with a known 
amount of metabolite concentration (0.5, 1, 2, 5, 10, 20, 50, 100, 200 and 400 pg/µl) 
was used (Figure 7). The limits of quantitation (LOQ) were 0.5 µg/l for oxo-MINP, 
oxo-MEHP, MODMOP, 5cx-MEPP; 1 µg/l for 7OH-MINP, 5OH-MEHP, MEHP; 1.3 
µg/l for MHDMOP, 7cx-MINP, 1.5 µg/l for MINP; 2.5 µg/l for MnBP, MBZP and 5 µg/l 
for 2cx-MMHPP.  
Figure 8 shows a chromatogram of all investigated metabolites phthalate metabolites.  
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Figure 7. Example of calibration curve of MnBP.  
 
Figure 8. Chromatogram of phthalate metabolites [100 pg/µl]. 
 
2I3I4 Additional control measurements in indoor air 
An indoor air sample (3.6 l/min, 1.32 m³ over 6 h) of both pigpens was collected once 
on a glass fiber filter and additionally on polyurethane foam by using a GGP sampler. 
The analytical separation of phthalates was performed by gas chromatography with 
subsequent detection by electron impact mass spectrometry in accordance with VDI 
guideline 4301-6 (2012). The indoor air phthalate concentration in the pigpens 
ranges between 50-59 ng/m³ (details are shown in Table 13). 
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The measurement and analysis were performed by the Department of Environmental 
Health Protection from the Berlin-Brandenburg State Laboratory.  
 
Table 13. Phthalate indoor air concentration  
 LOD [ng/m³] Pigpen A [ng/m³] Pigpen B [ng/m³] 
DnBP 10 50 59 
BBzP 10 < < 
DEHP 50 < 55 
DiNP 50 < < 
<: below LOD 
 
2I3I5 Additional control measurements in animal food 
To avoid further exposure to plasticizers, the potatoes and Fresubin were analyzed 
with an accredited method (PA 1.605) by the Fraunhofer Institute for Process 
Engineering and Packaging IVV. The method is described briefly as follows: For the 
phthalate determination, 10 g of potatoes were extracted by acetone (dest.) and n-
hexane. Deuterium labeled standards (D4-DEHP and D4-DBP) were added. The 
supernatant was analyzed by GC-MS (Shimadzu QP5000; SIM-mode; Column ZB-
50, 30 m x 0.25 µm; Temperature: 80 °C/1min - 10 °C/min – 300 °C/17 min). The 
results are shown in Table 14.  
 
Table 14. Determination of phthalate concentration in food  
 Potatoe sample  Fresubin  
BBzP < LOD (< 5 ng/g) < LOD (< 10 ng/g) 
DnBP < LOD (< 2 ng/g) < LOD (< 20 ng/g) 
DEHP < LOD (< 5 ng/g) < LOD (< 20 ng/g) 
DINP < LOD (< 5 ng/g) < LOD (< 600 ng/g) 
 
2I4 Statistical analysis  
The evaluation of urine analysis was performed with MultiQuant 2.1.1 (AB SCIEX) 
and for calculations and statistics Microsoft Excel 2010 and SPSS 19 (IBM) were 
used.  
The phthalate values were normally distributed (Kolmogorov–Smirnov–Test, Dust: 
n=35; BBzP: p= 0.539; DEHP: p=0.275; DINP: p=0.142; DnBP: p= 0.708, Food: n=7; 
BBzP: p=0.684; DEHP: p=0.997, DINP: p=0.762; DnBP: p=0.918), therefore for 
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group comparisons (dust uptake versus dietary uptake), a T-test for independent 
samples was used.  
Calculation of the phthalate uptake using urinary metabolite concentration  
To reach the absolute concentration [µg], the measured concentration of the urine 
samples [ng/ml] was multiplied by the corresponding excreted urine volume [ml] and 
then divided by 1000. Subsequently, each absolute concentration was added to the 
other urine samples. The sum of the metabolite [µg] was then divided by the 
molecular weight [g/mol] of the metabolite. The excreted metabolite [µmol] was 
divided by the administered amount from the parent compound [µmol]. The sum was 
multiplied by 100 to calculate the percentage dose uptake [%]. The complete dose 
uptake, from dose application to 24 hours post dose and 24 hours to 38 hours post 
dose, was calculated. The molecular weight of the phthalates and their metabolites 
are given in Table 15.  
 
 
Table 15. Molecular weight of phthalates and their metabolites  
Phthalate g/mol Metabolite g/mol 
BBzP 312.37 MBzP 256.25 
DEHP 390.56 MEHP 278.34 
  5OH-MEHP 294.34 
  oxo-MEHP 292.32 
  5cx-MEPP 308.30 
  2cx-MMHP 308.32 
DINP 418.62 MINP 292.38 
  oxo-MINP 306.35 
  7OH-MINP 308.37 
  7cx-MINP 322.35 
DnBP 278.35 MnBP 222.23 
 
Toxicokinetic calculations  
The elimination half-life time (t½) of the metabolites was estimated by using the 
following equation  
 
ke= elimination constants 
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It was observed that after 24 hours post dose, the excretion of the metabolites 
increased again. Therefore the half life time was calculated for each elimination 
period (first half life time: Cmax to 16 hours post dose, second half life time: 24 to 38 
hours). The urine sample with the highest concentration (Cmax) is defined as tmax.  
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3I Results  
Mainly no metabolites were detected in the control urine samples or only a 
concentration (< 1.5 µg/l) was detected. The control urine samples were not used for 
any calculation. Quality control samples were in good agreement with the expected 
concentration of 20 pg/µl (recovery was between 80 - 110 %). The coefficient of 
variation or the duplicate urine samples was below 15 %.  
3I1 Excretion of plasticizers in the dust experiment 
The mean administered dose of plasticizers in dust ranged from 2.7 µg (BBzP) to 
4057 µg (DEHP) respectively (Table 16). For quality control, a reference dust was 
measured (SRM dust). The recovery in this dust sample was between 80 - 100 %. 
Additionally the dust samples were diluted (1:100), the diluted and undiluted 
concentration were in good agreement. The dust samples were analyzed in 2014 and 
2016. Both measurements resulted in the same amount of concentration.  
Table 16. The mean and standard deviation (SD) of the administered dose in µg 
 BBzP DEHP DnBP DINP 
Dust A 17.3 ± 0.5 3989.4 ± 113.1 40.5 ± 1.1 636 ± 18 
Dust B 84 ± 7.2 4056.7 ± 346.2 23.3 ± 2 219.2 ± 18.7 
Dust C 27.7 ± 1.5 3874.3 ± 214.8 132.8 ± 7.4 941 ± 52.2 
Dust D 2.7 ± 0.1 3878.5 ± 86.2 33.4 ± 0.7 1404.3 ± 31.2 
Dust E 15.5 ± 0.8 3728.5 ± 187.7 7.7 ± 0.4 3340 ± 168 
For low molecular weighted phthalates, the mean urinary excretion of the applied 
dose in dust measured 27.7 ± 17.6 % for BBzP and 52.2 ± 18 % for DnBP. The mean 
for high molecular weighted phthalates as DEHP is 43 ± 11 % and for DINP 47 ± 26 
%, respectively. As shown in Figure 9, the mean excretion of BBzP, DnBP, DEHP 
and DINP for dust sample A was 22.5 ± 7 %, 55 ± 19 %, 44 ± 8.5 %, 75 ± 21 %; for 
dust sample B: 28 ± 12 % (BBzP), 42 ± 14 % (DEHP), 58 ± 12 % (DnBP); for dust 
sample C: 25 ± 13 % (BBzP), 45 ± 16 % (DEHP), 52 ± 28 % (DINP), 39 ± 15 % 
(DnBP), for dust sample D: 9.6 % (BBzP), 39 ± 6 % (DEHP), 37 ± 9 % (DINP) 46 ± 
15 % (DnBP), for dust sample E: 54 ± 10 % (BBzP), 44 ± 6 % (DEHP), 23 ± 5 % 
(DINP), 69 ± 21 % (DnBP). Table 17 shows the urinary excretion for each plasticizer 
and dust sample in every single pig. Because of conflicting results in dust sample B, 
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DINP was rejected. For the same reason, the DnBP measurement was excluded for 
pigs 2, 4 and 5 in dust sample E.  
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Figure 9. Excretion of phthalates in relation to the applied dose in %.  
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Figure 9. Excretion of phthalates in relation to the applied dose in %.  
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Table 17. The sum of phthalate metabolite excreted in urine (in % of the applied dose of each dust 
sample) 
 
 
 
 
 
 
 
  BBzP DEHP DINP DnBP 
Dust A Pig 1 23.9 49.6 93.9 49.0 
 Pig 2 24.1 44.0 96.7 30.6 
 Pig 3 25.3 35.2 60.5 75.6 
 Pig 4 29.7 54.6 62.3 82.3 
 Pig 5 14.2 45.1 67.7 59.0 
 Pig 6 11.9 30.5 45.9 48.2 
 Pig 7 29.0 49.8 96.7 82.6 
Mean±SD  22.5 ± 7 44 ± 8.5 75 ± 21 55 ± 19 
Dust B Pig 1 39.2 48.0 - 71.0 
 Pig 2 27.8 34.2 - 71.1 
 Pig 3 22.6 33.9 - 40.2 
 Pig 4 29.9 64.25 - 56.5 
 Pig 5 11.9 33.2 - 43.7 
 Pig 6 47.6 55.1 - 63.7 
 Pig 7 15.9 26.2 - 58.8 
Mean±SD  28 ± 12 42 ± 14  58 ± 12 
Dust C Pig 1 8.7 32.0 29.2 23.6 
 Pig 2 28.5 41.1 57.9 47.6 
 Pig 3 44.7 68.8 99.0 41.5 
 Pig 4 14.5 32.5 27.7 30.6 
 Pig 5 18.2 37.2 33.4 27.4 
 Pig 6 19.1 38.1 39.6 35.5 
 Pig 7 41.7 70.3 80.3 74.5 
Mean±SD  25 ± 13 45 ± 16 52 ± 28 39 ± 15 
Dust D Pig 1 9.4 36.5 30.4 30.0 
 Pig 2 11.2 39.1 38.0 49.4 
 Pig 3 17.6 29.4 30.1 47.8 
 Pig 4 8.0 39.3 29.2 31.6 
 Pig 5 4.6 38.3 38.7 59.0 
 Pig 6 - 37.8 38.8 38.8 
 Pig 7 12.4 50.8 56.1 71.6 
Mean±SD  9 ± 6 39 ± 6 37 ± 9 46 ± 15 
Dust E Pig 1 52.5 48.6 22.2 71.9 
 Pig 2 60.2 50.2 29.7 - 
 Pig 3 42.0 38.7 17.0 65.3 
 Pig 4 55.0 39.6 22.6 - 
 Pig 5 60.0 42.8 22.8 - 
 Pig 6 67.1 57.3 30.6 96.0 
 Pig 7 41.0 37.5 15.7 43.4 
Mean±SD  54 ± 10 44 ± 6 23 ± 5 69 ± 21 
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3I2 Excretion of phthalates in the food experiment 
The food sample contained 19 µg BBzP, 2500 µg DEHP, 31 µg DnBP and 857 µg 
DINP. The solution was afterwards analyzed by gas chromatograph to confirm the 
concentration.  
As given in detail in Table 18 and Figure 10, the mean excreted amount of the 
applied dose in urine is 37 ± 23 % of BBzP, 53 ± 15 % of DEHP, 43 ± 12.5 % of DINP 
and 39 ± 16 % of DnBP. Similar to dust, pig 3 was left out for DnBP and BBzP. Pig 2 
was excluded for DnBP, respectively.  
Table 18. The sum of phthalate metabolites excreted in urine (in % of the applied dose of the food 
sample) 
 BBzP DEHP DINP DnBP 
Pig E 69.2 61.3 50.8 61.2 
Pig F 30.0 78.6 53.7 - 
Pig G - 59.0 56.6 - 
Pig H 63.5 47.0 26.9 50.6 
Pig I 19.1 37.7 27.7 32.6 
Pig K 24.5 53.8 48.8 23.5 
Pig L 17.8 36.3 35.8 26.2 
Mean ±SD 37±23 53±15 43±12.5 39±16 
 
 
Figure 10. Excretion of phthalates in relation to the applied food sample in %.  
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3I3 Comparison the urine excretion of phthalates in dust and food 
No significant differences between the quantities of plasticizers excreted in urine in 
the two experiments (dust and food ingestion) were observed (BBzP: p = 0.262; 
DEHP p = 0.358; DINP p = 0.055 and DnBP: p = 0.764). By testing the individual 
metabolites, only MEHP showed a slight significance (p = 0.05) (MBzP: p = 0.263; 
5OH-MEHP: p = 0.839; 5oxo-MEHP: p = 0.08; 5cx-MEPP: p = 0.394; MINP: p = 
0.021; oxo-MINP: p = 0.064; OH-MINP: p = 0.415; cx-MINP: p = 0.660 and MnBP: p 
=0.531). Table 19 and Figure 11 provide a detailed overview of the metabolite 
excretion of each pig in relation to the applied dose in dust and food.  
Table 19. Mean ± SD of metabolite excretion in related to the applied dose in dust and food [%] 
DEHP  Pig MEHP 5OH-MEHP oxo-MEHP 5cx-MEP 
  Dust Food Dust Food Dust Food Dust Food  
 1 9.0 ± 3.4 15.6 12.0 ± 2.5 17.7 8.3 ± 1.7 12.2 13.2 ± 1.7 15.8 
 2 7.6 ± 1.8 13.0 9.0 ± 2.5 9.4 8.7 ± 0.9 18 16.4 ± 1.9 38.3 
 3 9.0 ± 3.1 12.8 10.7 ± 5.0 12.0 9.0 ± 3.0 15.1 12.3 ± 5.0 19.1 
 4 6.8 ± 2.5 6.5 11.5 ± 6.0 8.8 7.7 ± 1.5 7.7 20.0 ± 5.4 24 
 5 4.8 ± 2.0 3.3 5.3 ± 1.6 5.8 9.0 ± 1.0 6.8 20.2 ± 2.4 21.8 
 6 5.2 ± 2.4 4.7 9.5 ± 3.0 13.9 9.1 ± 4.2 10.5 19.5 ± 3.5 24.7 
 7 7.4 ± 4.2 2.8 7.6 ± 2.8 8.3 12.1 ± 4.0 6.7 17.3 ± 4.8 18.5 
 Total 7.1 ± 3.0 8.4±5.3 9.4 ± 4.0 10.8±4 9.2 ± 2.8 11±4.3 17.3 ± 4.8 23.2 ± 7.4 
DINP  MINP oxo-MINP OH-MINP cx-MINP 
  Dust Food Dust Food Dust Food Dust Food  
 1 34.0 ± 34.5 36.8 1.5 ± 0.7 2 3.5 ± 2.2 6.3 4.7 ± 1.5 5.7 
 2 45.6 ± 32.0 41.5 3.6 ± 0.7 2.6 1.1 ± 0.6 3.2 5.2 ± 2.0 6.4 
 3 44.8 ± 35.6 48.6 2.6 ± 0.4 3 1.2 ± 0.5 1.6 3.0 ± 1.3 3.4 
 4 26.5 ± 19.0 20.3 2.2 ± 1.0 1.1 3.8 ± 1.3 3 2.8 ± 1.2 2.4 
 5 32.0 ± 20.3 22 3.5 ± 1.6 3 2.4 ± 0.7 1.3 2.8 ± 1.0 1.5 
 6 28.0 ± 10.6 36.6 3.0 ± 1.7 2.5 4.0 ± 1.8 5.8 3.4 ± 1.7 4.0 
 7 50.3 ± 34.7 28.2 3.8 ± 2.4 2.3 2.0 ± 0.9 1 6.0 ± 3.0 4.4 
 Total 37.3 ± 26.4 33.4±10.4 2.9 ± 1.4 2.3±0.6 2.6 ± 1.6 3.2±2.1 4.0 ± 2.0 4.0±1.7 
BBzP, DnBP MBzP MnBP   
  Dust Food Dust Food   
 1 26.7 ± 19.0 70 48.0 ± 24.0 57   
 2 30.4 ± 18.0 30 48.5 ± 17  -   
 3 30.4 ± 12.0 - 48.9 ± 15 -   
 4 27.4 ± 18.0 63.5 47.7± 20.3 47.8   
 5 21.8 ± 21.8 19 41.0 ± 10.5 33   
 6 29.0 ± 27.5 24.5 51.5 ± 28.4 23.5   
 7 28.0 ± 13.8 17.8 53.6 ± 15.0 26.2   
 Total 27.7 ± 17.7 37.3 ± 23 48.7 ±18.0 37.4±14.4  
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Figure 11. Percentage excretion of the sum of (A) BBzP-, (B) DnBP-, (C) DEHP- and (D) DINP-
metabolite in relation to the applied dose of dust. 
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Figure 11. Percentage excretion of the sum of (A) BBzP-, (B) DnBP-, (C) DEHP- and (D) DINP-
metabolites in relation to the applied dose of dust. 
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3I4 Toxicokinetics of phthalates 
An example of the time course of the urinary excretions is given in Figure 12 (dust 
sample) and Figure 13 (food sample). The time course for each pig and applied 
sample is given in the appendix. In the dust samples, the metabolites of DEHP, 
DINP, BBzP and DnBP had the highest concentration within the first five hours after 
application. In the food sample, the highest concentration for DEHP and DINP was 
observed 24 hours post dose, the LMW phthalates had their highest concentration 
within the first five hours. The metabolism of phthalates can underlie a two-phase 
elimination. The initial increase of metabolite excretion is observed after three to five 
hours, followed then by a decrease. A second increase occurs normally 24 hours 
post dose. Because of this, the half-life time was calculated for both peak times. A 
detailed description of the toxicokinetic is given in the appendix (Section AI2).  
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Figure 12. Time course of urinary phthalate metabolite excretion after dust administration. 
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Figure 13. Time course of urinary phthalate metabolite excretion after food administration. 
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3I4I1 Butyl benzyl phthalate 
Dust: 
The urinary concentration maximum (cmax) occurred 3 ± 0.8 hours post dose. The 
estimated half-life time of MBzP was about 5 ± 4.3 hours. Within the first 24 hours, 27 
± 17 % of the applied BBzP dose was excreted as MBzP. Between 24 and 38 hours, 
only 0.1 ± 0.3 % of the dose was eliminated.  
Food: 
The maximum concentration in urine was observed after 4.2 ± 3 hours post dose. 
The half-life time was about 4 ± 2.3 hours. 45 ± 37.8 % of the dose was eliminated 
within the first 24 hours. On the second day no MBzP was detectable in the urine. 
3I4I2 Di-n-butyl phthalate 
Dust: 
The maximum concentration was reached after 2.8 ± 1 hours post dose. The first 
estimated half-life time was around 3.3 ± 3.3 hours, whereas 24 hours later the 
second half life time was reached within 6.2 ± 5 hours. During the first 24 hours, 46 ± 
17.6 % of the given dose was eliminated via urine, while 24-38 hours post dose only 
2.7 ± 3 % of the given dose was detected. 
Food:  
After 2.8 ± 0.4 hours post dose, the urinary maximum concentration was reached. 
The half-life time was estimated at 3.2 ± 2.1 hours. The second half-life time (24 
hours post dose) was 3.8 ± 1.2 hours. 34.3 ± 17 % of the absorbed dose was 
metabolized and eliminated within in the first 24 hours. On the second day only 1.3 ± 
2 % of the dose was detected in urine. 
3I4I3 Bis (2-etylhexyl) phthalate  
Dust 
Tmax were estimated for MEHP, 5OH-MEHP, oxo-MEHP and 5cx-MEPP as 3 ± 1 
hours, 2.7 ± 1 hours, 3.6 ± 1.3 hours and 5 ± 5 hours. 4.2 ± 2 hours (MEHP), 4.7 ± 
2hours (5OH-MEHP), 6.3 ± 3.8 hours (oxo-MEHP) and 5.3 ± 2.7 hours (5cx-MEPP) 
were determined as the half-life time in the first excretion phase. The second 
excretion period was 24 hours post dosing, the mean half-life time was in decreasing 
order 5.6 ± 3 hours (MEHP), 5 ± 1.8 hours (5OH-MEHP), 5.2 ± 2 hours (oxo-MEHP), 
5.1 ± 2 hours (5cx-MEPP). Within the first 24 hours, 40.2 ± 10.2 % from the DEHP 
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dose were excreted as 16.3 ± 4.6 % 5cx-MEPP, 8.7 ± 3.8 % 5OH-MEHP, 8.4 ± 2.6 % 
oxo-MEHP and 6.7 ± 3 % MEHP. After 24 hours, 2.7 ± 1 % DEHP dose was found in 
urine. It was mainly excreted as 1 ± 0.4 % 5cx-MEPP followed by 0.7 ± 0.3 % oxo-
MEHP, 0.6 ± 0.4 % 5OH-MEHP and 0.4 ± 0.2 % MEHP.  
Food: 
After 24 hours, the maximum concentration was reached. The elimination half-life 
was 5.4 ± 1.4 hours for MEHP, 4.6 ± 1 hours for 5cx-MEPP, 6 ± 1.6 hours for oxo-
MEHP and 5.2 ± 1.3 hours for 5OH-MEHP. Within the first 24 hours, 38.6 ± 7.4 % 
DEHP of the applied dose was mainly excreted as 5cx-MEPP (18 ± 5.3 %), oxo-
MEHP (7.6 ± 2.6 %), 5OH-MEHP (7 ± 4.2 %) and MEHP (6 ± 3.6 %). 24-38 hours 
after the sample administration, 13.5 ± 5.2 % DEHP was found in urine (5.3 ± 2.2 % 
5cx-MEPP, 3.3 ± 1.8 % oxo-MEHP, 2.4 ± 1.7 % MEHP and 2.4 ± 1.6 % 5OH-MEHP). 
To sum up, for all pigs administered the dust and food samples, the metabolites were 
excreted in the following order of abundance: monoester < hydroxyl < oxo < carboxy. 
Figure 14 illustrates the measured amount of the DEHP metabolites excreted in both 
dust and food samples. 
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Figure 14. A) DEHP-metabolites in relation to the given dose in dust samples B) The excreted DEHP-
metabolites in relation to the applied dose in food.  
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3I4I4 Diisononyl phthalate 
Dust: 
DINP metabolites reached their mean maximum concentration at 4.2 ± 4 hours 
(MINP) 5.5 ± 6.6 hours (oxo-MINP), 4 ± 4.2 hours (7OH-MINP) and 4.8 ± 5.6 hours 
(cx-MINP) after dose application. 
The estimated halt-life time for the first elimination phase was similar for all 
metabolites: 5.3 ± 2 hours (MINP), 6.6 ± 4 hours (oxo-MINP), 5.6 ± 3 hours (7OH-
MINP) and 5.8 ± 3.4 hours (7cx-MINP). The second elimination phase occurred 24 
hours post dose. The half-life time was estimated at 5.3 ± 2 hours for MINP, 6.6 ± 4 
hours for oxo-MINP, 5.5 ± 3 hours for 7OH-MINP and 5.8 ± 3.4 hours for 7cx-MINP. 
During the first 24 hours, 43.4 ± 24 % of the dose was excreted as 34 ± 25 % MINP, 
3.7 ± 2 % 7cx-MINP, 2.7 ± 2.3 % 7OH-MINP and 3 ± 1.6 % oxo-MINP. After 24 hours 
to 38 hours, only 3.6 ± 2.5 % DINP as 3 ± 2.4 % MINP, 0.27 ± 0.25 % oxo-MINP, 
0.24 ± 0.2 % 7cx-MINP and 0.23 ± 0.3 % 7OH-MINP was excreted.  
Food: 
The maximum concentration for MINP and oxo-MINP was reached 24 hours after 
sample administration. The tmax for 7OH-MINP and oxo-MINP occurred after 24.5 ± 
1.5 hours and 25.7 ± 4.5 hours, respectively. The half-life time for excreted MINP was 
about 6 ± 1.6 hours, for oxo-MINP about 7.3 ± 3.5 hours, for 7OH-MINP about 7.5 ± 
3.7 hours and for 7cx-MINP about 5.2 ± 2.8 hours. 
36.8 ± 14.8 % of the DINP dose was excreted in the first 24 hours mainly as MINP 
(30.3 ± 15.1 %), followed by 7cx-MINP (2.8 ± 1.3 %), 7OH-MINP (2.1 ± 1.5 %) and 
oxo-MINP (1.5 ± 0.4 %). On the second day, 15.3 ± 6.3 % DINP (12.3 ± 6 % MINP, 
1.1 ± 0.5 % 7cx-MINP, 1 ± 0.73 % 7OH-MINP and 0.8 ± 0.3 % oxo-MINP) was 
eliminated by urine.  
 
In conclusion, for dust samples, the metabolites were excreted in the order of 
abundance: hydroxyl < oxo < carboxy< monoester. For the food sample, the order of 
abundance differed: oxo< hydroxyl< carboxy< monoester. Figure 15 illustrates the 
amount of the DINP metabolites excreted in the samples of dust (Fig 15. A) and food 
(Fig. 15. B), respectively. 
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Figure 15. A) The sum of the excreted DINP-metabolites in relation to the applied dust samples B) 
The DINP metabolites in the food sample.  
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4I Discussion  
Oral bioavailability is defined as the fraction of an ingested contaminant in a certain 
carrier matrix which reaches systemic circulation. Oral bioavailability is influenced by 
three different points:  
1.  The contaminant is released from the matrix during digestion in the 
  gastrointestinal tract. This step is also known as bioaccessibility  
2.  The absorption of the bioaccessible fraction by the intestinal epithelium.  
3.  The metabolism of the contaminant in the intestine and liver  
The bioaccessibility is mainly affected by the matrix, whereas the absorption rate and 
metabolism are influenced by the chemical properties of the contaminant [94]. 
4I1 Bioavailability of phthalates in dust  
The mean bioavailability of the applied dose in dust was 27.7 ± 17.6 %, 52.2 ± 18 %, 
43 ± 11 % and 47 ± 26 % for BBzP, DnBP, DEHP and DINP respectively. In this 
study, our collecting time was limited to 38 hours. We were still able to detected 
metabolites in the last urine sample and have to assume that the excretion of the 
applied phthalates was not completed. This might lead to a minor loss in 
bioavailability data. The applied dose was orientated to the TDI of DEHP. Every dust 
sample was applied with a similar DEHP concentration but the amount of dust varied. 
In consideration of intra-individuality, the bioavailability of DEHP has a low variation 
and seems to have a good reproducibility. It is assumed that this observation obtains 
as well for the other investigated phthalates. It is also noticeable that the 
bioavailability of DEHP and DINP is fairly similar (median: DEHP 39.3 %, DINP: 38.3 
%). We also observed a saturation process: the higher the applied DINP dose, the 
lower the bioavailability. In dust sample A, a mean of 636 ± 18 µg of DINP was 
administrated with a remarkably high bioavailability of 75 ± 21% compare to dust 
sample E with an applied dose of 3340 ± 168 µg of DINP and bioavailability of 23 ± 5 
%. The applied amount of dust varies between 0.5 g (dust A) and 0.78 g (dust E). To 
clarify if the concentration or the amount of dust underlies a saturation process dust 
sample A and C were compared. Dust sample A and dust sample C were 
administered in a similar amount (0.54 g) and the concentration varies from 636 ±18 
µg (dust A) to 941 ± 52.2 µg (dust C). The bioavailability of DINP was determined for 
dust sample A of 75 ± 21 % and for dust sample C of 52 ± 28 %. Those results might 
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indicate that the saturation process depends on the applied concentration and not on 
the given amount of matrix. These findings compare favorably with Mckee et al. [11], 
who also observed a decreased absorption rate by an increasing orally administered 
dose in rats. Forty-nine % of the given DINP dose (50 mg/kg) was observed, whereas 
there was only an uptake of 39 % of the 500 mg/kg DINP dose. We did not observe 
this effect in other phthalates.  
Our results showed a higher bioavailability than in vitro digestions test. In an in vitro 
digestion test a bioaccessibility of 2.24 - 12.6 % for DnBP, BBzP, DEHP, and DINP in 
dust was observed [80]. In another in vitro digestion test, slightly higher values were 
noted (10 – 15 % for BBzP, DnBP, DEHP and DINP) [87].  
Both in vitro digestion tests used dust particles with a diameter of 63 µm, where the 
highest bioaccessibility is suspected. In this study, the same particle size was used, 
therefore an influence of the particle size fraction can be excluded.  
As shown in this study, as well as in the in vitro digestion test, bioavailability varies 
according to the phthalate under investigation.  
The in vitro digestion test is often used as a method to investigate bioavailability; it 
enables similar conditions for an experiment series and reduces inter-individual 
variances. Bioaccessibility is influenced in any case by natural physiological 
conditions like transfer time, pH, enzyme production and diffusion barrier. Changes in 
those parameters influence the results of in vitro digestions tests [95]. Additionally, in 
in vitro digestion tests, only the bioaccessibility of a compound can be determined 
but, e.g. the absorption rate cannot be included, which is an important influencing 
factor of bioavailability.  
In a comparison study of five different in vitro digestion tests, a wide range in the 
bioaccessibility of heavy metals in three different soil samples was observed (e.g. 
Arsenic : 6 - 95 %, 1 – 19 % and 10 – 59 %). It was concluded that the pH value is 
probably the reason of the differences in the bioaccessibility. Increased 
bioaccessibility through the presence of food components (in this case milk powder) 
was also tested. Compared to the different pH values, the presence of food 
components has a minor influence [91]. In this study the dust sample was applied 
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with a portion of food which may lead to a slight increase of bioaccessibility as 
compared with dust uptake by e.g. putting a dust covered toy in their mouth.  
The different results between this study and the in vitro digestion tests indicate that 
the chosen parameters for the in vitro test (pH, acid mixture, residual of time, ratio 
between matrix and liquid.) might not match the simulation of digestion, which could 
lead to an underestimation of the bioavailability. At the current state of knowledge, in 
vitro digestion tests cannot accurately simulate the bioaccessibility of human 
digestion (in vivo). Thus, the results of an in vitro digestion test should be interpreted 
with caution and considered only as indicative values.  
In an arsenic bioavailability study conducted by Freeman et al. [96], cynomolgus 
monkeys received a dust, soil and soluble sodium arsenate sample via a gelatin 
capsule gavage and an intravenous injection. The mean absolute bioavailability 
(corrected by the intravenous injection) for house dust was 19 % and for the soluble 
arsenic was 68 %. These results suggest that the compounds in matrix dust have a 
reduced health risk based on its reduced bioavailability. In this study, it was not 
possible to calculate the absolute bioavailability. The results of the intravenous 
injection were not trustworthy because of difficulties in administration and therefore 
excluded from this study.  
Additionally, arsenic and phthalates have completely different chemical properties, 
which makes it difficult to compare these results. Nonetheless, it can still be 
demonstrated that the ingestion of dust results in a noticeable exposure to chemicals.  
 
4I2 Bioavailability of phthalates in food sample  
In our study, the mean bioavailability was 37.3 ± 23 % (BBzP), 39 ± 16 % (DnBP), 53 
± 15 % (DEHP) and 43 ± 12.5 % (DINP). In a review, Wormuth et al. [24] 
summarized that the bioavailability of phthalate uptake through diet ranged between 
69 – 78 % (BBzP), 64 – 73 % (DnBP), 15 – 95 % (DEHP) and 75 – 90 % (DINP). 
These reported levels are higher than those found in our study. Our food sample was 
a 1 % ethanol-phthalate mixture and potatoes. For this study, we are aware that the 
food sample might not be as representative as a normally prepared dish. Because of 
adding a solution to the sample, we might disregard the process of how much the 
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contaminant is released from the matrix food. However, the research focus was more 
on dust. In our study we could not observed a difference in the bioavailability of the 
matrix dust and food. Huwe et al. [70] observed similar findings in rats with 
polybrominated diphenyl ethers (PBDEs) in matrix dust and oil. They observed that 
PBDEs in dust bioconcentrate in rat fat tissue to the same or higher extent as PBDEs 
applied with oil. PBDEs accumulate in the body, which could influence the results of 
this study. The physicochemical characteristics of PBDEs are different to phthalates, 
which makes it difficult to compare these results. Anyway the study indicates a trend, 
which should be verified by further research.  
 
4I3 Toxicokinetics of phthalates 
Although the bioavailability in food and dust is similar, the toxicokinetic profile differs. 
In dust samples, the maximum concentration was reached three to five hours post 
dose and in the food sample, after three to four hours (LMW phthalates) and 24 
hours for HMW phthalates. The delayed release or metabolism of the phthalates 
could be caused by the use of the carrier ethanol. It is noted that in other orally 
applied toxicokinetic studies, the highest concentration was reached shortly after 
administration [13, 59, 66, 69]. In any case, a biphasic metabolism was observed. 
The second increase was observed 24 hours after dose application. This effect can 
be explained by the fact that the metabolites underlie an enterohepatic circulation 
and there was no overnight collection of urine (eight hours break). Morning urine 
seems to be more highly concentrated in general. The half-life times, tmax and Cmax, 
correspond to the results in other studies [13, 59, 66, 69, 97].  
Compared to studies of humans, we observed variations of DINP metabolism. The 
metabolites were excreted in an order of abundance: OH-MINP < oxo-MINP < cx-
MINP < MINP in dust. In food, the oxo-MINP metabolite came first and then the OH-
MINP group. In a toxicokinetic study conducted by Koch et al. [69], it was reported 
that metabolite excretion is in the order of abundance: MINP < oxo-MINP < cx-MINP 
< OH-MINP. Our results indicate that piglets are slower in metabolizing DINP 
compared to humans. In a DEHP toxicokinetic study with rats, dogs and pigs, it was 
also shown that in pigs the eliminations of radioactivity were slowest [98]. Another 
difference was identified in the DEHP metabolism. The carboxy metabolite 5cx-
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MEPP was the main excreted metabolite. In this study, the excretion was in an order 
of abundance of MEHP< 5OH-MEHP< 5oxo-MEHP< 5cx-MEPP whereas in general, 
the following order of abundance obtains: MEHP< 5 oxo-MEHO < 5cx-MEPP < 5OH-
MEHP. However there is no indication that this has an effect on the bioavailability. 
Further research should verify if the metabolite excretion order is influenced by the 
pigs, which might have a different metabolism.  
Additionally it should be clarified if e.g. 5cx-MEPP was also identified as the 
structurally analogues 5cx-MEPTP, which is a metabolite of a terephthalate (DEHTP) 
a structural isomer of DEHP. In a DEHTP- toxicokinetic study was shown that 13 % 
of the excreted 5cx-MEPTP is in shares comparable to the 5cx-MEPP [99]. The 
presence of DEHTP in dust might lead to an unintended background exposure which 
was probably measured as 5cx-MEPP of DEHP. This could lead to a slight 
overestimation of the bioavailability of DEHP.  
 
4I4 Dust as an exposure source  
In this experiment, we were able to show that dust is an exposure source for 
phthalates. The background exposure was kept as low as possible and verified by a 
control urine sample, therefore assuring that the main phthalate exposure was 
caused by the administered dust samples. Our results agree with biomonitoring and 
risk assessment studies where dust was already suspected to be an exposure 
source. 
With our bioavailability data and assuming an daily dust intake of 60 mg and an 
average bodyweight of 13 kg, the mean intake for BBzP, DEHP, DINP and DnBP 
through dust would be 0.07 ± 0.09 µg/kg b.w., 12.1 ± 2.1 µg/kg b.w., 3.7 ± 0.6 µg/kg 
b.w. and 0.16 ± 0.13 µg/kg b.w.. This intake would contribute 0.01% (BBzP), 24.1 % 
(DEHP), 2.4 % (DINP) and 1.7 % (DnBP) to the TDI of each phthalate. For a 
cumulative risk assessment, the hazard Index (HI)4 was calculated with an daily 
intake of 0.07 µg/kg/d BBzP, 12.1 µg/kg/d. DEHP, 3.7 µg/kg/d DINP and 0.16 µg/kg/d 
                                            
4 Hazard Index (HI) is the sum of the hazard quotients (HQ), which is defined as   
. An HI <1 is will not result in negative health effects, while an HI > 1 can pose a health risk.  
100. https://www.epa.gov/national-air-toxics-assessment/nata-glossary-terms, 20.06.2017. 
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DnBP and their corresponding TDI’s. The HI was 0.2. It shows that the phthalate 
exposure only through dust does not pose a health risk.  
Kang et al. [87] calculated an average daily dose (ADD) of DEHP through non-dietary 
ingestion of house dust for preschool children in China. Under a moderate dust 
ingestion rate (0.05 gram per day), none of the children would exceed the reference 
dose (RfD) of 20 µg/kg b.w./d, but for a high dust ingestion rate (0.2 g/d), 13 % of the 
dust samples would result in a higher ADD than the RfD. Considering the 
bioaccessibility of phthalates in dust, no dust sample would result in exceeding the 
RfD. DnBP showed also no indication of exceeding the RfD (RfD: 100 µg/kg b.w./d). 
Kang et al. estimated that moderate dust intake and high dust intake contributes 28.4 
% and 61.3 % to the overall DEHP exposure. 74.8 % (under moderate dust intake) 
and 92.2% (high dust intake) of the total DnBP exposure was contributed through 
dust intake. In a similar study conducted by Wang et al. [80], the daily intake of 
phthalates in house dust was evaluated. For toddlers, the highest phthalate exposure 
was calculated with 5.4 ng/kg b.w./d, 102 ng/kg b.w./d and 5800 ng/kg b.w./d for 
BBzP, DnBP and DEHP, respectively. Dust ingestion was identified as a major 
contributor for non-dietary DEHP exposure with 81.4 - 96.4 % of the total intake. By 
taking the dietary exposure into account, the dust ingestion would contribute 36.5 % 
of the DEHP exposure (calculated for adults). For the low molecular phthalate DnBP, 
indoor air seems to be the major contributor of the non-dietary DnBP exposure. By 
calculation of the ADD, 5 % of the dust samples exceed the RfD (20 µg/kg b.w./d for 
DEHP) by a high dust intake rate (200 mg/d). For a moderate dust intake (100 mg/d), 
no dust sample would exceed the RfD. In a China-USA comprehensive study, the 
daily dust intake for toddlers was 83.7 ng/kg b.w./d, 0.9 ng/kg b.w./d and 949 ng/kg 
b.w./d for DnBP, BBzP and DEHP in China, in the USA, the values were generally 
higher with 64.4 ng/ kg b.w./d (DnBP), 104 ng/kg b.w./d (BBzP) and 1500 ng/kg 
b.w./d (DEHP) [84]. Except for the DEHP value, the values are in good agreement to 
those reported by Wang et al. [80]. The ingestion of dust contributes only 2 – 5 % of 
the total DEHP and DnBP exposure in China and 1 – 16 % of the total DnBP, 3 – 21 
% of the total BBzP and 10 – 58 % of the total DEHP intake in the USA. In another 
biomonitoring study by Fromme et al. [47], the phthalate content in air and dust from 
German daycare centers was measured. The phthalate exposure was identified by 
the excreted metabolites in 663 urine samples of children attending the investigated 
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daycare centers. No child exceeded the TDI values for DEHP and DnBP, only one 
child had a higher DINP value than the TDI and 16 children exceeded the TDI of 
DiBP. The daily intake was determined by back-calculation based on the amount of 
the urinary phthalate metabolites. The average intake was calculated with the median 
and the high intake with 95th percentile of urinary metabolite concentration. Those 
intakes were compared with the TDI. In the “high” total intake scenario, less than 50 
% of the TDI was reached, except for DiBP (62 %). It also showed a significant 
correlation between the concentration in indoor air and dust and the excreted urinary 
metabolite concentration on a bivariate analysis, but using a multiple linear 
regression model, only indoor air was correlated with urinary metabolite 
concentration [47].  
Bekö et al. [4] estimated the phthalate intake of children in urine through the 
exposure of dust ingestion, inhalation and dermal absorption. They analyzed dust 
and children’s urine samples and assumed a daily dust uptake of 60 mg. The daily 
total intake, which was estimated by the urinary metabolite concentration, was 
compared to the estimated daily uptake from the indoor environment (dust ingestion, 
inhalation and dermal absorption). DEHP had the highest intake resulting from dust 
ingestion. It was also shown, that 75 % and 95 % of the weekly indoor intake of BBzP 
and DEHP entered the body through dust ingestion, whereas for low molecular 
phthalates like DnBP and DiBP, 80% of the weekly indoor intake (WIindoors) occurs via 
dermal absorption from air. Bekö et al. [4] assumed that indoor exposure 
corresponds to 2.2 % (DEHP), 13 % (DnBP) and 0.01 % (BBzP) of the TDI. In a 
similar study conducted by Langer et al. [48], a significant correlation between 
phthalates concentration in house dust (home and daycare samples) and urinary 
metabolite concentration in the urine of 441 Danish children (DnBP-MnBP p<0.05, 
BBzP-MBzP p<0.001) was found. Compared to the other studies, a correlation 
between DEHP metabolites and dust concentration was not observed.  
All these studies concluded that dust is a contributor to phthalate exposure, 
especially for non-dietary exposure and for toddlers. They also indicate that indoor air 
is a major contributor to DnBP and DiBP exposure. All the mentioned studies were 
based on different amounts of dust ingestion (60-200 mg/d), which leads to a 
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different assumption of how much dust exposure contributes to the total phthalate 
exposure. 
 
4I5 Dust exposure compared to food exposure  
In several studies it was shown that the predominant intake source for DEHP intake 
is diet. As shown in a duplicate diet study performed by Fromme et al. [101], a 
significant correlation was determined between the DEHP concentration in food and 
the concentration in urine samples (where the DEHP intake was back-calculated). 
For DnBP, no correlation and for DiBP, a weak correlation was observed. An infant-
based duplicate diet study showed that for DiBP and DnBP, the dietary intake only 
comprised about 24 – 32 % of the total intake. For BBzP, it was only 4 % of the total 
intake. However, for DEHP, dietary intake is the dominant contributor [102]. A risk 
characterization of dietary uptake by Heinemeyer et al. [62] showed that less than 1 
% of German adults may exceed the tolerable daily intake of 50 µg/kg b.w. DEHP. 
Furthermore, they concluded that the average external dietary exposure of DEHP 
ranged between 3-14 µg/kg b.w./d and that 30 to 40 % of the total intake is 
contributed by the ingestion of dust. Wormuth et al. [24] assumed that for infants and 
toddlers, the main source for BBzP is dust (>70 %) and food might contribute 20 % to 
the total BBzP exposure. For children and adults, the main source is food (60 - 73 %) 
and contaminated indoor air (26 %). For infants, toddlers and children, the mouthing 
of soft plastics is up to 90 % responsible for DINP take up, whereas teenagers and 
adults are mainly exposed through dust (>30 %) and air (~30 %). The main source 
for DnBP exposure is food (40 – 90 %). For infants, toddlers and children, indoor air 
(20 - 40 %) and dust (10 %) are additional exposure sources. Female teenagers and 
adults are exposed by personal care products too (15 – 50 %). Food is the most 
important source for DEHP (50 – 98 %), for infants and toddlers, dust (>35 %) and 
toys (8 – 9 %) also contribute to the DEHP exposure. DINP is used as a substitution 
for DEHP. It is expected that exposure pathways are becoming more similar, thus 
food will also become the major exposure source for DINP.  
Reviewed by Oomen et al. [86], the DEHP exposure through food and water is 
almost 3 - 16 µg/kg b.w./d for adults and 12-26 µg/kg b.w./d for children. Compared 
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to the TDI value of 50 µg/kg b.w., a child has a share of 24-52 % of the TDI through 
this pathway.  
It has been assumed that through infant formula consumption, newborns and infants 
are exposed to 2.4 - 1.8 µg/kg b.w./d DINP [30]. Several human biomonitoring 
studies confirm that the main phthalate exposure takes place through ingestion. A 
duplicate diet study conducted by Fromme et al. [102] showed that the DEHP 
concentration in highly contaminated food lay around 4.7 µg/kg b.w. (95th percentile) 
and the high intake from biomonitoring data was 4.9 µg/kg b.w.. Koch et al. [103] 
tested in a 48 hour fasting study the phthalate exposure using excretion data in urine. 
The high molecular weight phthalates DEHP, DINP and DIDP showed a fast 
elimination rate and remained at a low level, whereas the low molecular weight 
phthalates DMP, DEP, BBzP, DnBP and DiBP had a rising and declining 
concentration in urine. These results indicated that the main exposure of high 
molecular weight phthalates occurs by food ingestion, whereas the others seem to 
have another exposure source, like personal care products or through indoor air and 
dust. 
 
4I6 Phthalate in dust as a health risk? 
In the last years, the toxicokinetic properties, sources and health effects of phthalates 
have been intensively investigated. In general, the average body burden of 
phthalates does not exceed the TDI value. A decreasing urinary phthalate 
concentration in recent years indicates a declining exposure to some phthalates. 
Nonetheless, especially children continue to show high urinary phthalate levels 
compared to adults. Children have a high food and water requirements per unit of 
body mass, an increased hand to mouth activity, a higher ventilation rate and 
unintended dust ingestion rate than adults. It is suspected that dust is an additional 
but minor exposure source for children. Our findings support this hypothesis. 
However, the question of phthalate exposure through dust posing a potential health 
risk still remains open. As mentioned above, several risk assessment studies 
concluded, that the ingestion of dust does not lead to an intake that exceeds TDI or 
RfD values. It was also observed that from daily intake calculations (including dust 
and dietary intake), children should have exceeded the TDI, but the urinary 
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concentration showed no higher values than the TDI for one phthalate or a 
combination of several phthalates. Additionally, in most of risk assessments, a 
bioavailability of 100% was assumed. Our study indicates that the bioavailability of 
phthalates in dust is less than 60%. In consideration of an estimated intake of 60 mg 
of dust per day, it can be concluded that dust is an additional phthalate exposure 
source, but it is still a minor contributor to the total exposure (0.01 % of the TDIBBzP, 
24.1 % of the TDIDEHP, 2.4 % TDIDINP, and 1.7 % of the TDIDnBP). Another important 
consideration is that only through the ingestion of dust, the hazard index was at 0.2, 
which also means that no negative health effects should be expected. Especially for 
the HMW phthalates such as DEHP and DINP, the dietary uptake is still the main 
exposure source for all age groups. On the contrary, for the LMW phthalates such as 
BBzP, DnBP and DiBP, it shows that the indoor environment, including dust, has an 
influence on the total exposure, but without a negative health effect.  
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5I Conclusion and future perspectives  
According to the US-EPA, toddlers have an unintended daily uptake of approximately 
60 mg dust which contains a variety of pollutants. Especially phthalates are present 
in high amounts and could pose a potential health risk. Currently, there is no 
information about the bioavailability of phthalates in the matrix dust. Our results show 
that the bioavailability of phthalates is much higher (~30 – 60 %) compared to in vitro 
digestion tests (~10 – 20 %). Furthermore, it is noticeable that the bioavailability of 
DEHP, for example, does not vary within the dust samples. A dose dependence 
uptake of DINP was observed. In other phthalates, we did not find this effect. Further 
research is needed to understand the underlying mechanism of the dose 
dependence DINP uptake. Moreover it should be clarified if this effect also occurs in 
humans and how much does it influence the DINP exposure.  
Biomonitoring studies indicate that children are highly exposed to phthalates but they 
do not normally exceed the TDI. In addition to diet and toys, dust could be an 
additional source of plasticizers for toddlers. However, because the limited amount of 
dust uptake does not normally lead to children exceeding the TDI, phthalate 
exposure through dust does not pose a health risk for children.  
The next step of research should be focused on determining the actual amount of 
ingested dust. On dust uptake, the quantity ingested has a higher influence on the 
exposure of phthalates than their bioavailability. In this study we focused only on 
bioavailability, thus there was only one test using a higher amount of dust where we 
noticed an increase of the phthalate exposure. But under realistic situations, where a 
child ingests approximately 60 mg dust during the day, it might contribute to a 
constant background exposure similar to indoor air without noticing an increase or 
decrease of urinary phthalate excretion. Further research is still needed in regard to 
how much indoor air contributes to the phthalate exposure, especially DnBP and 
DiBP. Additionally, further research should also address the bioavailability of other 
contaminants in dust, to determine whether dust poses a general exposure source or 
just in the case of phthalates.  
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Table A1. Experiment timetable. Letters are dust samples, numbers are pigs 
05.10.2015 
8pm Pigs: 
1,2,3 and 4 
into the 
metabolite 
cage 
06.10.2015 
6am-10pm 
B-1 
C-2 
D-3 
E-4 
07.10.2015 
6am-8pm 
B-1 
C-2 
D-3 
E-4 
08.10.2015 
8pm Pigs: 
5,6 and 7 
into the 
metabolite 
cage 
09.10.2015 
6am-10pm 
E-5 
C-6 
B-7 
10.10.2015 
6am-8pm 
E-5 
C-6 
B-7 
11.10.2015 
8pm Pigs: 
1,2,3 and 4 
into the 
metabolite 
cage 
12.10.2015 
6am-10pm 
A-1 
B-2 
E-3 
C-4 
13.10.2015 
6am-8pm 
A-1 
B-2 
E-3 
C-4 
14.10.2015 
8pm Pigs: 
5,6 and 7 
into the 
metabolite 
cage 
15.10.2015 
6am-10pm 
C-5 
A-6 
E-7 
16.10.2015 
6am-8pm 
C-5 
A-6 
E-7 
17.10.2015 
8pm Pigs: 
1,2,3 and 4 
into the 
metabolite 
cage 
18.10.2015 
6am-10pm 
C-1 
E-2 
B-3 
A-4 
19.10.2015 
6am-8pm 
C-1 
E-2 
B-3 
A-4 
20.10.2015 
8pm Pigs: 
5,6 and 7 
into the 
metabolite 
cage 
21.10.2015 
6am-10pm 
D-5 
B-6 
A-7 
22.10.2015 
6am-8pm 
D-5 
B-6 
A-7 
23.10.2015 
8pm Pigs: 
1,2,3 and 4 
into the 
metabolite 
cage 
24.10.2015 
6am-10pm 
D-1 
A-2 
C-3 
B-4 
25.10.2015 
6am-8pm 
D-1 
A-2 
C-3 
B-4 
26.10.2015 
8pm Pigs: 
5,6 and 7 
into the 
metabolite 
cage 
27.10.2015 
6am-10pm 
Food 
sample for 
Pig 5,6 
and 7 
28.10.2015 
6am-8pm 
Food 
sample for 
Pig 5,6 
and 7 
29.10.2015 
8pm Pigs: 
1,2,3 and 4 
into the 
metabolite 
cage 
30.10.2015 
6am-10pm 
Food 
sample for 
Pig 1,2,3 
and 4 
31.10.2015 
6am-8pm 
Food 
sample for 
Pig 1,2,3 
and 4 
1.11.2015 
8pm Pigs: 
5,6 and 7 
into the 
metabolite 
cage 
02.11.2015 
6am-10pm 
A-5 
D-6 
C-7 
03.11.2015 
6am-8pm 
A-5 
D-6 
C-7 
04.11.2015 
8pm Pigs: 
1,2,3 and 4 
into the 
metabolite 
cage 
05.11.2015 
6am-10pm 
E-1 
D-2 
A-3 
D-4 
06.11.2015 
6am-8pm 
E-1 
D-2 
A-3 
D-4 
07.11.2015 
 
08.11.2015 
8pm Pigs: 
5,6 and 7 
into the 
metabolite 
cage 
09.11.2015 
6am-10pm 
IV-Injection  
For Pigs 
5,6 and 7 
10.11.2015 
6am-8pm 
IV-Injection  
For Pigs 
5,6 and 7 
11.11.2015 
6am-10pm 
IV-Injection  
For Pig 
1,2,3 and 4 
12.11.2015 
6am-8pm 
IV-Injection  
For Pig 
1,2,3 and 4 
13.11.2015 
8pm Pigs: 
5,6,7 into 
the 
metabolite 
cage 
14.11.2015 
6am-10pm 
B-5 
E-6 
D-7 
15.11.2015 
6am-8pm 
B-5 
E-6 
D-7 
 
 
 
 
Table A2. Used Standards for food sample 
Plasticizer  Brand CAS-Number 
BBP Fluka 85-68-7 
DEHP Fluka 117-81-7 
DnBP Fluka 84-74-2 
DINP Fluka 28553-12-0 
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Table A3. Transition settings of the investigated and labeled phthalate metabolites RT: retention time; 
DP: declustering potential; EP: entrance Potential; CEP: collision cell entrance potential; CE: Collision 
energy  
RT  GROUP Q1 
MASS 
[DA] 
Q3 
MASS 
[DA] 
ID DP EP CEP CE 
8.3 5CX-MEPP 
307 
113 QUAL. 
-15 -10 -12.71 
-40 
159 QUANT. -22 
311 
113 
D4 LAB. 
QUAL. 
-15 -10 -12.86 
-36 
159 
D4 LAB. 
QUANT. -18 
8.6 
5-OH-
MEHP 
293 
121 QUANT. 
-30 -10 -12.21 
-28 
145 QUAL. -20 
297 
125 
D4 LAB. 
QUANT. 
-30 -10 -12.35 
-22 
145 
D4 LAB. 
QUAL. -24 
9.1 
7CX-
MMEHP 
321 
121 QUAL. 
-35 -10 -13.22 
-30 
173 QUANT. -18 
325 
125 
D4 LAB. 
QUAL. 
-35 -10 -13.36 
-32 
173 
D4 LAB. 
QUANT. -18 
9.1 2CX-MMHP 
307 
113 QUAL. 
-10 -10 -12.71 
-42 
159 QUANT. -14 
311 
113 
D4 LAB. 
QUAL. 
-10 -10 -12.86 
-36 
159 
D4 LAB. 
QUANT. -16 
9.2 MIBP 
221 
77 QUANT. 
-20 -10 -9.62 
-24 
134 QUAL. -20 
225 
81 
D4 LAB. 
QUANT. 
-20 -10 -9.76 
-28 
138 
D4 LAB. 
QUAL. -20 
9.2 
5-OXO-
MEHP 
291 
121 QUANT. 
-25 -10 -12.14 
-22 
143 QUAL. -22 
295 
124 
13C4 LAB. 
QUANT. 
-25 -10 -12.28 
-22 
143 
13C4 LAB. 
QUAL. -20 
9.3 MNBP 
221 
77 QUANT. 
-25 -10 -9.62 
-26 
121 QUAL. -20 
225 
71 
D4 LAB. 
QUAL. 
-25 -10 -9.76 
-20 
79 
D4 LAB. 
QUANT. -28 
9.4 
7OH-
MMEOP 
307 
77 QUAL. 
-25 -10 -12.71 
-46 
121 QUANT. -32 
311 
81 
D4 LAB. 
QUAL. 
-25 -10 -12.86 
-44 
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125 
D4 LAB. 
QUANT. -28 
9.9 MCDMHP 
335 
121 QUAL. 
-20 -10 -13.72 
-30 
187 QUANT. -28 
339 
125 
D4 LAB. 
QUAL. 
-20 -10 -13.87 
-40 
187 
D4 LAB. 
QUANT. -20 
10.1 MBZP 
255 
77 QUAL. 
-20 -10 -10.84 
-34 
107 QUANT. -18 
259 
77 
13C4 LAB. 
QUAL. 
-20 -10 -10.98 
-36 
107 
13C4 
LAB.QUANT
. -20 
10.1 7OXO-MINP 
305 
77 QUAL. 
-25 -10 -12.64 
-42 
121 QUANT. -26 
309 
81 
D4 LAB. 
QUAL. 
-25 -10 -12.79 
-42 
125 
D4 LAB. 
QUANT. -22 
   9.8 
- 10.8 
MHDMOP 
321 
77 QUAL. 
-45 -10 -13.22 
-48 
121 QUANT. -30 
325 
81 
D4 LAB. 
QUAL. 
-45 -10 -13.36 
-50 
125 
D4 LAB. 
QUANT. -26 
11.0 MODMOP 
319 
77 QUAL. 
-30 -10 -13.15 
-52 
121 QUANT. -22 
323 
81 
D4 LAB. 
QUAL. 
-30 -10 -13.29 
-44 
125 
D4 LAB. 
QUANT. -32 
14.3 MEHP 
277 
127 QUAL. 
-25 -10 -11.63 
-22 
134 QUANT. -24 
281 
127 
13C4 LAB. 
QUAL. 
-25 -10 -11.78 
-30 
137 
13C4 
LAB.QUANT
. -22 
14.8 MINP 
291 
77 QUANT. 
-30 -10 -12.13 
-38 
139 QUAL. -28 
295 79 
13C4 
LAB.QUANT
. -30 -10 -12.28 -38 
141 
13C4 LAB. 
QUAL. -24 
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Table A4. List of the used standards  
Native standard Internal standard 
MEHPa 13C2-MEHPa 
5OH-MEHPa D4-5-OH-MEHPb 
5 oxo–MEHPa 13C4-5-oxo-MEHPa 
MBzPa 13C2- MBzPa 
MnBPa 13C2-MnBPa 
MINPa 13C2-MINPa 
2cx-MMHPb D4-2cx-MMHPb 
5cx-MEPPb D4-5cx-MEPPb 
OH-MINPb D4-7OH-MINPb 
oxo-MINPb D4-oxo-MINPb 
cx-MINPb D4-cx-MINPb 
a)Campridge Isotope, b)Biochemisches Institute für Umweltcarginogene 
 
 
AI2 Results 
The detailed description of toxicokinetics of phthalates 
AI2I1 Butyl benzyl phthalate 
Pig 1 
Dust: 
The urinary concentration maximum occurred 3.5 ± 0.7 hours post dose. The 
estimated half-life time of MBzP was about 7.8 ± 9.1 hours. 
Within the first 24 hours, 26.6 ± 18.6 % of applied BBzP dose was excreted as MBzP. 
Between 24 to 38 hours only 0.2 ± 0.5 % of the Dose was eliminated.  
Food: 
Two hours after dose administration, the maximum concentration was observed in 
urine. The half-life time was about 2.4 hours. 69.2 % of the applied dose was 
eliminated within the first 24 hours. On the second day no MBzP was detectable in 
the urine.  
 
Pig 2  
Dust:  
MBzP reached its maximum concentration 2.2 ± 0.5 hours post dose. The average t½ 
was about 5 ± 3.6 hours. On the first day, 30.3 ± 18.1 % of the applied BBzP dose 
was eliminated as MBzP. On the second day, only 0.08 ± 0.17 % of dose was found 
in urine.  
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Food: 
The concentration maximum was reached three hours post dose. Based on the 
excretion profile, it was not possible to calculate the half-life. The uptake and 
metabolism took place in the first 24 hours where 30 % of the BBzP dose was 
excreted  
 
Pig 3  
Dust: 
The concentration maxima was reached 3.2 ± 1 hours post dose. The estimated half-
life time was about 2.8 ± 0.5 hours. On the first sampling day, 30.2 ± 12.3 % and on 
the second day 0.3 ± 0.6 % of the applied BBzP dose was detected. 
Food: 
It was more than the applied dose excreted in urine.  
 
Pig 4  
Dust: 
The urinary concentration maximum was observed 2.5 ± 0.6 hours post dose. t½ was 
determined about 6.4 ± 6.6 hours. 27.4 ± 18.1 % of the applied dose was completely 
excreted on the first day.  
Food: 
The maximum concentration was reached three hours post dose. 4.4 hours was 
determined as elimination half-life time. In Sum 63.4 % of the BBzP dose was 
completely excreted within 24 hours as MBzP.  
 
Pig 5  
Dust: 
Tmax was observed 3 ± 1.1 hours post dose and the half-life time was about 3.2 ± 0.6 
hours. In total, 18.2 ± 14.4 % of the dose was completely eliminated during the first 
day. 
Food: 
Within three hours, the maximum concentration was reached. The calculated half-life 
time was 2.2 hours. Similar to dust, the complete 0.2 % of the applied BBzP dose 
was excreted within 24 hours.  
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Pig 6  
Dust:  
MBzP reached its urinary Cmax at 2.7 ± 1 hours after dose. The t½ was estimated as 
7.1 ± 3.5 hours. 29 ± 27.4 % of the given dose was excreted in the first 24 hours. 
From 24 hours to 38 hours 0.1 ± 0.2 % of the given dose was detected in urine.  
Food: 
After ten hours the maximum concentration was reached. The half-life time was 
estimated with 8.4 hours. 24.5 % of the applied dose was completely excreted on the 
first day, on the second day no metabolites were detected.  
 
Pig 7  
Dust:  
Cmax was estimated after three hours post dose. The elimination half-life was 
determined around 3.4 ± 1.6 hours. During the first 24 hours, 28 ± 13.6 % of the 
given dose was detected. 
Food: 
Similar to the other piglets, Cmax was noticed after three hours post dose and t ½ was 
after 3.9 hours. The complete absorbed dose of 17.8 % was excreted within 24 
hours.  
 
AI2I2 Di-n-butyl phthalate  
Pig 1 
Dust:  
The maximum concentration was reached after 2.8 ± 0.8 hours post dose. The first 
estimated half-life time was around 3.3 ± 1.8 hours, whereas 24 hours later the 
second half life time was reached with 7.3 ± 4.8 hours.  
During the first 24 hours, 45 ± 21 % of the given dose was eliminated via urine, while 
24 - 38 hours post dose only 3.2 ± 3 % of applied dose was detected. 
Food:  
After two hours post dose the urinary maximum concentration was reached. The half-
life time was estimated for 1.8 hours. The second half-life time (24 hours post dose) 
was 3.8 hours. The complete absorbed dose of 56.8 % was metabolized and 
eliminated within in the first 24 hours. 
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Pig 2  
Dust:  
The highest concentration was 2.5 ± 0.6 hours post dose noticed. During the first 
elimination period, the half-life time was about 6.6 ± 7.6 hours, while at the second 
elimination phase, t½ was 6.3 ± 8.8 hours. The second elimination period occurred 11 
to 36 hours post dose (see table A5). 
43.7 ± 16.1 % of the applied dose was excreted in the first 24 hours. On the second 
day, 4.6 ± 5.9 % was detected.  
Food:  
More than 100 % of the applied dose was found  
 
Pig 3  
Dust:  
The concentration maxima was 2.6 ± 1.5 hours post dose noticed. t½ of the first 
elimination period was 1.9 ± 0.2 hours, while the second t½ was estimated with 2.6 ± 
0.2 hours and occurred 9 - 24 hours post dose (for details see table X).  
Within the first 24 hours, 45.7 ± 16.7 % of the given dose was eliminated. 24 - 38 
hours post dose, 3.1 ± 2.3 % of the applied dose was found in urine.  
Food:  
The uptake was more than the given dose  
 
Pig 4  
Dust:  
It took 2.2 ± 0.5 hours after dose administration to reach the maximum concentration. 
t½ of the first elimination phase was 1.9 ± 0.4 hours, the second elimination half-life 
time was 7.5 ± 9.2 hours and occurred 12 - 14 hours post dose  
On the first day, 46.6 ± 19.4 % of the applied dose was excreted, whereas on the 
second day, only 1.1 ± 1.5 % respectively. 
Food:  
The maximum concentration was reached three hours post dose. The elimination 
half-life time was determined with four hours. 
47.8 % of the dose was absorbed and metabolized and completely excreted within 
24 hours post dose.  
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Pig 5  
Dust:  
The maximum concentration was 3.2 ± 0.9 hours post dose observed. During the first 
elimination, the half-life time was determined at 2.5 ± 0.6 hours, the second t½ was 
calculated with 6.8 ± 4.3 hours (12-24 hours post dose).  
38.6 ± 10.7 % of the dose was determined in the first 24 hours. Only 2.2 ± 2.4 % was 
excreted on the second day, respectively.  
Food:  
Three hours post dose, the maximum of concentration was reached. The half-life 
time amounted 2.8 hours. 
21.3 % of the applied Dose was excreted in the first 24 hours as MnBP. After 24 
hours 2.4 % of the applied dose was eliminated.  
 
Pig 6  
Dust:  
The concentration maximum was observed 3.4 ± 1.7 hours post dose. t½ for the first 
excretion phase was about 4.4 ± 1.6 hours, the second t½  was 7.6 ± 2 hours (11 - 24 
hours post dose) 
50.5 ± 29 % of the applied dose was detected in 24 hours post dose. 0.9 ± 1.3 % was 
found on the second day.  
Food: 
The Cmax was determined three hours after dose administration. The estimated 
elimination half –life time was 8.7 hours. Within 24 hours, 23.5 % of the applied dose 
was detected in urine.  
 
Pig 7  
Dust:  
2.7 ± 0.5 hours post dose, the highest concentration was measured. During the first 
elimination phase, the half-life time was estimated around 2.1 ± 1.4 hours, the 
second above 5.6 ± 2.2 hours (24 h post dose). 
49.7 ± 13.4 % of the administrated dose was found in urine as MnBP. On the second 
day, only 3.8 ± 2.9 % was detected.  
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Food: 
Same as dust samples, the concentration maximum was reached three hours post 
dose. The first and second t½ was determined with 5.6 hours and 5 hours.  
22 % of the applied dose was detected in urine samples 24 hours post dose. 24 
hours to 38 hours post dose, only 4.2 % of the applied dose was identify and 
excreted as MnBP.  
 
A detail description of the toxicokinetic parameters of MBzP and MnBP, 
concentration maximum (Cmax) and it’s time appearance (tmax), half-life time (t½) in the 
first excretion and second period (second tmax [h] + second t ½) are given in Table A5.  
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Table A5. Detail description of kinetic parameters of BBzP and DnBP metabolism [Cmax in µg, tmax and 
t ½ in hour]. 
Dust  Pig MBzP MnBP 
  cmax tmax  t½  cmax tmax  t½  
A 1 0.7  2 3.4 2 4 24+5 
 2 0.9 2 6 3.1 2   
 3 0.9 3 2 5.5 3 2 24+3 
 4 1.4 2 2 9 2 2 14+1 
 5 0.5 4 4 3 4 4 
 6 0.3 2 5 2.5 2 4 
 7 1.6 3 2 4.9 3 2 
B 1 4.7 4 18.4 2.08 4 5.7 24+15.1 
 2 4.6 3 10 3 3 4 24+2 
 3 3.6 2 3 1.8 2 2 
 4 4.6 2 16 2.8 2 5 
 5 1.8 4 3 1.6 4 2 
 6 5 4 8 24+1 2.7 4 5 11+9 
 7 4.3 3 3 3 3 4 
C 1 1.1 - - - 12.1 3 2 24+5 
 2 2.1 2 2 14.7 2 18 36+0.5 
 3 2.6 5 3 1.8 5 2 12+3 
 4 1.2 3 2 11 3 2 12+14 
 5 0.9 2 4 5.6 2 3 24+4 
 6 0.9 2 5 6.3 2 3 28+6 
 7 2.6 3 3 18.7 3 2 24+7 
D 1 0.1 - - - 1.8 2 2 14+3 
 2 0.2 3 - - 4.7 3 3 
 3 0.1 2 - - 1.8 1 4 
 4 0.2 2 - - 2.8 2 2 
 5 0.1. 12 - - 4.4 3 2 12+9 
 6 0 - - 1.4 6 2 14+5 
 7 0.3  - 4.7 2 4 24+7 
E 1 2.3 3 3 1.8 3 2 
 2 2.7 2 2 1.9 2 2 11+2 
 3 1.3 3 3 0.9 2 2 
 4 1.6 3 5 1 32 2 
 5 2.2 2 3 2.1 2 5 
 6 4.4 3 5 2.6 3 2 
 7 1.4  6 0.6 3 - - 
Food 1 2.8 2 2.3 5.5 2 2.9 
 2 2.9 3 - 13 32 2 
 3 4 4 3 6.2 4 2 24+7 
 4 2.1 3 4 2.8 3 4 
 5 1.2 3 2 3.3 3 3 
 6 0.6 10 8 0.9 3 9 
 7 0.6 3 4 1 3 5 
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AI2I3 DEHP 
Pig 1  
Dust:  
MEHP and oxo-MEHP reached their maximum concentration after 3.4 ± 0.5 hours, 
5OH-MEHP and 5cx-MEPP had their tmax at 2.8 ± 0.8 hours. During the first 
elimination period, MEHP has a half-life time of 5 ± 2.4 hours, followed by 5cx-MEPP 
(5.2 ± 1 hours), 5OH-MEHP (5.3 ± 2.8 hours) and oxo-MEHP (7.7 ± 4.8 hours). In the 
second elimination phase, which normally occurred 24 hours after drug 
administration, the estimated mean half-life time for MEHP, oxo-MEHP, 5OH-MEHP 
and 5cx-MEPP was 4.4 ± 1 hours, 4.7 ± 0.7 hours, 4.6 ± 0.7 hours and 4.1 ± 0.5 
hours. Within the first 24 hours 40 ± 7.5 % of the applied DEHP dose was excreted 
as 12.6 ± 1.6 % 5cx-MEPP), 11.5 ± 2.3 % 5OH-MEHP, 7.6 ± 1.6 % oxo-MEHP, 8.4 ± 
3.33 % MEHP. Between the 24 hours to 38 hours post dose, 2.3 % of the applied 
Dose was excreted as 0.7 ± 0.2 % oxo-MEHP, 0.7 ± 0.3 % 5OH-MEHP, 0.6 ± 0.2 % 
5cx-MEPP, 0.5 ± 0.3 % MEHP. 
Food 
All metabolites reached their maximum concentration after 24 hours and have an 
elimination half –life time of four hours. Within the first 24 hours, 46 % of DEHP dose 
was excreted as 11.5 % MEHP, 8.9 % oxo-MEHP, 13.4 % 5OH-MEHP, 12.2 % 5cx-
MEPP. On the second day 15.3 % DEHP was eliminated as 4.1 % MEHP, 3.3 % oxo-
MEHP, 4.2 % 5OH-MEHP and 3.6 % 5cx-MEPP.  
 
Pig 2  
Dust: 
The mean Tmax for MEHP and 5OH-MEHP were determined after 2.4 ± 0.5 hours and 
for oxo-MEHP and 5cx-MEPP after 3 ± 1 hours after dust sample application.  
The mean half-life times for the first elimination period was estimated as 2.8 ± 0.9 
hours (MEHP), 3.5 ± 1.7 hours (5OH-MEHP), 5 ± 2.5 hours (oxo-MEHP), 6.1 ± 3.4 
hours (5cx-MEPP). During the second elimination, which normally was after 24 
hours, the mean half-life time was determined around 9.1 ± 3 hours for the primary 
metabolite MEHP, the secondary metabolite had a shorter half life time with 4.4 ± 0.8 
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hours (5OH-MEHP), 4.7 ± 1 hours (5cx-MEPP) and 4.8 ± 1.1 hours (oxo-MEHP), 
respectively.  
During the first 24 hours, 40 ± 6 % of the applied DEHP-Dose was eliminated as 15.8 
± 2 % 5cx-MEPP, 8.3 ± 0.8 % oxo-MEHP, 7.2 ± 1.6 % MEHP, 8.6 ± 2.5 % 5OH-
MEHP. After 24 hours only 1.8 ± 0.4 % of the administrated DEHP dose were 
eliminated as 0.6 ± 0.07 % 5cx-MEPP, 0.4 ± 0.08 % oxo-MEHP and 5OH-MEHP and 
0.4 ± 0.3 % MEHP.  
Food: 
The maximum concentration was determined 24 hours after dose application and the 
elimination half-life times ranged around three hours. 48.5 % of the DEHP dose was 
excreted in the first 24 hours. The main metabolite was 5cx-MEPP with 28.6 % 
followed by 11.6 % oxo-MEHP, 8.1 % MEHP and only 0.06 % 5OH-MEHP. In the 
sampling period 24 hours to 38 hours post dose: 20.8 % DEHP (9.7 % 5cx-MEPP, 
6.3 % oxo-MEHP, 4.8 % MEHP, 0.03 % 5OH-MEHP) was eliminated by urine. 
 
Pig 3  
Dust: 
MEHP, oxo-MEHP and 5cx-MEPP reached their mean maximum concentration after 
4.4 ± 1.3 hours post dose, while 5OH-MEHP had its tmax after 3 ± 1.2 hours.  
In the first elimination period, the mean half-life time at 4 ± 2.5 hours 5cx-MEPP, 5.7 
± 3.3 hours 5OH-MEHP, 6 ± 3.7 hours MEHP to 6.3 ± 3.3 hours oxo-MEHP. After 24 
hours, the second elimination phase occurred with a mean half-life of 3.75 ± 3.7 
hours for MEHP, 5.9 ± 3.6 hours for 5OH-MEHP, 7.4 ± 2.4 hours for 5cx-MEPP and 
7.7 ± 3.6 hours for oxo-MEHP. On the first day 38 ± 14.3 % of the DEHP dose were 
excreted in form of MEHP (8.4 ± 3 %), oxo-MEHP (8.2 ± 2.7 %), 5OH-MEHP (9.7 ± 
4.5 %) and 5cx-MEPP (11.5 ± 4.5 %). After 24 hours, only 3.3 ± 1.6 % of the DEHP 
dose was excreted as 0.9 ± 0.4 % 5cx-MEPP, 0.9 ± 0.5 % oxo-MEHP and OH-MEHP 
and 0.6 ± 0.2 % MEHP. 
Food:  
Twenty-four hours after dose application, all metabolites reached their maximum 
concentration. The half-life time for MEHP, oxo-MEHP, 5OH-MEHP and 5cx-MEPP 
was estimated as 5.4 hours, 6 hours, 5.4 hours and 4.5 hours. 41 % of the applied 
DEHP-dose was excreted within the first 24 hours (14.1 % 5cx-MEPP, 10.2 % oxo-
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MEHP, 9 % MEHP and 8.1 % 5OH-MEHP). In the sampling period from 24 to 38 
hours only 17.5 % of DEHP dose was eliminated by urine (5 % 5cx-MEPP and oxo-
MEHP, 3.8 % MEHP, 3.7 % 5OH-MEHP).  
 
Pig 4  
Dust: 
Tmax for MEHP and 5OH-MEHP were estimated as 2.4 ± 0.5 hours and three hours 
for oxo-MEHP. For 5cx-MEPP, the mean of tmax was determined as 11.2 ± 11.7 
hours.  
During, the first elimination period the half-life time was estimated for MEHP as 4.5 ± 
1.6 hours, 5cx-MEPP as 5.2 ± 1.4 hours, 5OH-MEHP as 5.3 ± 2 hours and oxo-
MEHP as 7 ± 2.6 hours. At the second elimination period (24 hours after dust 
application), the half-life time ranged between 5.3 ± 1.7 hours (5cx-MEPP), 5.6 ± 1.8 
hours (oxo-MEHP), 5.7 ± 2.6 hours (5OH-MEHP) and 6.5 ± 3.5 hours (MEHP). 
18.7 ± 5.2 % 5cx-MEPP, 10.8 ± 5.6 % 5OH-MEHP, 7.2 ±1.4 % oxo-MEHP, 6.5 ± 2.4 
% MEHP were excrete. 43.2 ± 12.2 % of the DEHP-doses was eliminated in the first 
24 hours. On the second collecting day 2.8 ± 1.1 % of the applied DEHP dose was 
excreted as 1.1 ± 0.4 % 5cx-MEPP, 0.7 ± 0.5 % 5OH-MEHP, 0.6 ± 0.2 % oxo-MEHP, 
0.3 ± 0.1 % MEHP.  
Food 
The maximum concentration was determined 24 hours after sample administration. 
The elimination half-life of six hours for MEHP, 6.3 hours for oxo-MEHP, 5.5 hours for 
5OH-MEHP and 5.3 hours for 5cx-MEPP was determined. On the first day, 18.4 % 
5cx-MEPP, 6.7 % 5OH-MEHP, 5.7 % oxo-MEHP, 5.1 % MEHP, in total 36 % of the 
applied DEHP dose was eliminated. On the second day only 11 % of applied DEHP 
dose was found in urine (5.6 % 5cx-MEPP, 2 % 5OH-MEHP and oxo-MEHP, 1.4 % 
MEHP) 
 
Pig 5  
Dust: 
Tmax (mean) were estimated for MEHP, 5OH-MEHP, oxo-MEHP and 5cx-MEPP as 
2.4 ± 0.5 hours, 3.2 ± 1.6 hours, 4.2 ± 1.8 hours and 5 ± 1 hours. 
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3.2 ± 0.3 hours (MEHP), 4 ± 0.9 hours (5OH-MEHP), 4.3 ± 0.8 hours (oxo-MEHP) 
and 4.6 ± 1.3 hours (5cx-MEPP) were determined as the mean half-life time in the 
first excretion phase. The second excretion period was 24 hours post dose, the mean 
half-life time was in decreasing order 7 ± 2.7 hours (MEHP), 4.8 ± 1 hours (5OH-
MEHP), 4.6 ± 0.8 hours (oxo-MEHP), 4.5 ± 0.8 hours (5cx-MEPP). Within the first 24 
hours, 35.1 % from DEHP dose were excreted as 19 ± 2.9 % 5cx-MEPP, 8.1 ± 0.82 
% oxo-MEHP, 4.6 ± 1.1 % 5OH-MEHP and 4.3 ± 1.5 % MEHP. After 24 hours 2.1 % 
DEHP dose was found in urine. It was mainly excreted as 0.9±0.2 % 5cx-MEPP 
followed by 0.5 ± 0.1 % oxo-MEHP, 0.2 ± 0.06 % 5OH-MEHP, 0.19 ± 0.04 % MEHP.  
Food: 
After 24 hours, the maximum concentration was reached. The elimination half-life 
was 5.3 hours for MEHP and 5cx-MEPP, eight hours for oxo-MEHP, 6.2 hours for 
5OH-MEHP. Within the first 24 hours, 29 % DEHP of the applied dose was mainly 
excreted as 5cx-MEPP (17.2 %), oxo-MEHP (5 %), 5OH-MEHP (4.5 %) and MEHP 
(2.4 %). 24 - 38 hours after the sample administration 8.6 % DEHP was found in 
urine (4.6 % 5cx-MEPP, 1.8 % oxo-MEHP, 1.3 % 5OH-MEHP and 0.9 % MEHP).  
 
Pig 6 
Dust: 
The mean maximum concentration for metabolites MEHP and 5OH-MEHP was 2.6 ± 
0.9 hours, 4 ± 2.3 hours for oxo-MEHP and 4.4 ± 2 hours for 5cx-MEPP.  
In the first elimination period, the mean half-life of MEHP, oxo-MEHP, 5OH-MEHP, 
5cx-MEPP were predicted as 4.3 ± 2.1hours, 8 ± 7.5 hours, 5.1 ± 1.8 hours and 7.1 ± 
4.8 hours.  
During the second elimination period (24 hours after dose application), the half-life 
time of MEHP, oxo-MEHP, 5OH-MEHP, 5cx-MEPP were determined as 4.2 ± 0.4 
hours, 4.3 ± 0.8 hours, 4 ± 0.6 hours and 4 ± 0.4 hours. During the first 24 hours, 
34.7 % DEHP of the applied dose were eliminated. In Detail: 18 ± 3.6 % 5cx-MEPP, 
8.4 ± 3.9 % oxo-MEHP, 8.7 ± 2.9 % 5OH-MEHP and 4.8 ± 2.4 % MEHP. After 24 
hours, 1.4 ± 0.5 % 5cx-MEPP, 0.7 ± 0.4 % oxo-MEHP, 0.7 ± 0.3 % 5OH-MEHP, 0.3 ± 
0.1 % MEHP. To sum it up, on the second day only 3.2 ± 0.9 % DEHP of the applied 
Dose was measured in urine.  
Food: 
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After 24 hours, tmax for all metabolites was reached. The elimination half-life time was 
5.8 hours, 6.5 hours, 5.7 hours and 4.8 hours for MEHP, oxo-MEHP, 5OH-MEHP and 
5cx-MEPP. Within the first 24 hours, the elimination of the applied DEHP dose was 
38.7 % (18.8 % 5cx-MEPP, 9.9 % 5OH-MEHP, 6.7 % oxo-MEHP, 3.3 % MEHP). 
After 24 to 38 hours, 15 % was excreted (5.8 % 5cx-MEPP, 4.1 % 5OH-MEHP, 3.7 % 
oxo-MEHP, 1.4 % MEHP) 
 
Pig 7  
Dust: 
The mean maximum concentration were found at three hours for 5cx-MEPP and oxo-
MEHP, 2.6 ±0.5 hours for 5OH-MEHP and for 2.8 ±0.4 hours MEHP after dust 
application  
The median half-life was in increasing order 3.5 ± 1.1 hours (MEHP), 4.3 ± 1.7 hours 
(5OH-MEHP), 5 ± 2.5 hours (5cx-MEPP) and as 5.6 ± 2.6 hours (oxo-MEHP) with the 
highest half life time. After 24 hours the second elimination period was determined. 
The mean half-life times ranged between: 4.3 ± 2 hours, 4.7 ± 1.4 hours, 4.8 ± 1.4 
hours and 6.2 ± 3.2 hours for MEHP, 5OH-MEHP, oxo-MEHP and 5cx-MEPP. Within 
the first 24 hours, 44 ± 15.8 % of the DEHP dose was eliminated as 19 ± 5.5 % 5cx-
MEPP, 11 ± 4 % oxo-MEHP, 7 ± 2.6 % 5OH-MEHP. On the second day, 3.5 % 
DEHP were mainly excreted as 5cx-MEPP (1.2 ± 0.4 %), followed by oxo-MEHP (1 ± 
0.4 %), 5OH-MEHP (0.5 ± 0.2 %) and MEHP (0.3 ± 0.1 %).  
 
Food: 
Similar to the other piglets, tmax was estimated 24 hours after dose administration. In 
increasing order the elimination half-life ranged from 5.5 hours, 6.6 hours, 6.8 hours 
to 7.8 hours for 5cx-MEPP, 5OH-MEHP, oxo-MEHP and MEHP. On the first sampling 
day, 30 % of DEHP dose as 15.8 % 5cx-MEPP, 6.8% 5OH-MEHP, 5.4 % oxo-MEHP 
and 2.2 % MEHP). On the second day only 6 % of the applied dose was excreted as 
mainly 5cx-MEPP (2.6 %) followed by 5OH-MEHP (1.4 %), oxo-MEHP (1.3 %) and 
MEHP (0.6 %). 
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A detail description of the toxicokinetic parameters, concentration maximum (Cmax) 
and it’s time appearance (tmax), half-life time (t½) in the first excretion and second 
period (24 hours plus second t ½) are given in Table A6. 
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Table A6. Detail description of kinetic parameters of DEHP metabolism [Cmax in µg, tmax and t ½ in hours]. 
Dust  Pig MEHP oxo-MEHP 5OH-MEHP 5cx-MEPP 
  cmax tmax  t½  cmax tmax  t½  cmax tmax  t½  cmax tmax  t½  
A 1 42.3 3 5 24+4 43.2 3 7 24+4 88.3 2 5 24+4 67 2 5 24+4 
 2 60.1 2 4 14+12 47 2 7 24+6 59.8 2 5 24+6 85.6 4 9 24+6 
 3 52.1 3 2 24+10 44.8 3 4 24+8 38.2 3 3 24+8 69 3 3 24+9 
 4 87.6 2 3 24+12 54.1 3 5 24+8 64.5 2 4 24+7 113.7 3 6 24+6 
 5 34 3 3 24+4 48 4 3 24+4 24 3 4 24+4 122.5 4 4 24+3 
 6 17 2 5 24+4 28.2 3 7 24+4 34.3 2 4 24+4 62.6 3 6 24+4 
 7 49.2 3 3 32+2 98.2 3 4 24+5 72 3 3 24+5 154.2 3 3 24+4 
B 1 43.3 4 8.8 24+5 47.5 4 16 24+5 61.9 4 10 24+5.3 73.8 4 6 24+4 
 2 34.6 3 4 14+11 36.7 3 8 24+4 47.2 3 5 24+4 45.8 3 10 24+5 
 3 31.8 6 12 36+1 24 6 5 24+11 50.9 2 11 36+1 51.2 6 4 24+9 
 4 47.3 2 5 24+6 33.7 3 10 24+6 100.9 2 8 24+5 130 24 4 
 5 12.7 2 4 24+6 35.1 6 4 24+5 18.5 2 5 24+5 101.5 6 4 24+5 
 6 31.6 2 8 24+4 55.6 4 20 24+4 58.6 2 8 24+4 94.6 4 14 24+4 
 7 37.6 3 3 24+6 49.6 3 4 24+5 53.2 3 3 24+5 78.1 3 3 24+4 
C 1 45.9 3 2 24+6 53.5 3 4 24+5 124.3 3 3 24+5 112.7 3 3 24+5 
 2 72.7 2 2 12+8 57.7 2 2 12+6 86.6 2 1 24+4 27.4 2 3 24+4 
 3 88.5 5 5 24+5 68.4 5 12 24+4 95.7 2 3 12+10 114.4 5 3 12+7 
 4 26.8 3 6 24+3 37.8 3 7 24+3 45.5 3 7 24+3 100.8 24 2 
 5 30.6 2 3 24+11 33.7 6 5 24+6 15.3 6 5 24+6 88.5 6 6 24+6 
 6 25.2 2 2 28+4 43.7 8 1 28+3 37.2 2 3 28+3 79.8 8 1 24+4 
 7 103 3 3 24+7 106.1 3 4 24+6 75 3 3 24+7 152.2 3 4 24+5 
D 1 27.3 4 4 24+3 29.8 4 5 24+4 46.7 2 4 24+4 59.1 2 5 24+3 
 2 49 3 2 14+10 72.3 4 4 24+4 73 3 3 24+4 137.4 4 4 24+5 
 3 36.2 5 7 36+1 33.4 5 4 14+11 35.7 5 6 24+8 44.9 5 1 14+8 
 4 41.7 2 3 24+5 31.5 3 5 24+3 55.6 2 3 24+4 91.6 3 4 24+4 
 5 33.4 3 3 24+6 59.3 3 4 24+4 56.1 3 3 24+4 124.6 4 3 24+4 
 6 15.4 4 3 24+4 18.7 2 6 11+5 34.4 4 4 24+4 96.6 4 5 24+3 
 7 53.8 2 4 24+4 60.8 2 7 24+4 52.7 2 5 24+4 89.9 2 3 
E 1 86.5 3 4 24+4 58.7 3 6 24+5 93.2 3 4 24+5 110.4 3 6 24+4 
 2 78 2 2 24+4 76.3 4 4 24+4 121.2 2 3 24+4 136.7 2 4 24+4 
 3 37.5 3 4 28+3 32.5 3 7 24+4 44.9 3 5 24+4 43 3 8 24+3 
 4 33.3 3 6 24+6 39 3 9 24+7 57.7 3 4 12+10 80.5 2 5 12+8 
 5 45 2 3 24+6 45.1 2 5 24+4 50.2 2 3 24+5 84.1 5 5 24+4 
 6 100 3 4 24+5 113 3 6 24+5 141.2 3 5 24+5 137 3 9 24+4 
 107 
 
 7 24.9 3 5 28+3 48.1 3 10 28+3 27 2 7 28+3 70.9 3 9 12+11 
Food 1 53.8 24 4 53 24 4.5 78.8 24 4 71.6 24 4 
 2 69.9 24 3 101.,1 24 3 53.7 24 3 267.7 24 3 
 3 47.5 24 5 69.5 24 6 31.8 24 5 107.8 24 4.5 
 4 17.2 24 6 31.8 24 6 36.3 24 5.5 106.5 24 5 
 5 11.2 24 5 19.6 24 8 16 24 6 76.5 24 5 
 6 15 24 6 38.1 24 6.5 55 24 6 111.5 24 5 
 7 6.8 24 8 19.3 24 7 21.2 24 7 50 24 5.5 
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AI2I4 Diisononyl phthalate  
Pig 1 
Dust: 
All metabolites of DINP reached their mean maximum concentration at 3.2 ± 0.5 
hours (MINP and Oxo-MINP) and 2.7 ± 0.5 hours (7OH-MINP and cx-MINP) post 
dose. 
The estimated half-life time for the first elimination phase was similar for all 
metabolites: 5.6 ± 1.7 hours (MINP), 5.7 ± 1.5 hours (oxo-MINP), 5.1 ± 1.5 hours 
(7OH-MINP), 6 ± 1.3 hours (7cx-MINP). The second elimination phase occurred 24 
hours post dose. The half-life time was estimated for MINP (4.7 ± 0.7 hours), 4 ± 0.3 
hours oxo-MINP, 3.8 ± 0.8 hours 7OH-MINP, 4.5 ± 0.6 hours 7cx-MINP. During the 
first 24 hours, 40 ± 31 % of the Dose was excreted as 32 ± 32 % MINP, 4.4 ± 1.4 % 
7cx-MINP, 3.4 ± 2 % 7OH-MINP and 1.5 ± 0.6 % oxo-MINP. After 24 hours to 38 
hours only 6.4 % DINP as 5 ± 5.5 % MINP, 0.6 ± 0.3 % 7cx-MINP, 0.4 ± 0.2 % 7OH-
MINP and 0.2 ± 0.1 % oxo-MINP was excreted.  
Food: 
The maximum concentration was reached 24 hours after sample administration. 
MINP was excreted with a half-life time of 4.5 hours, oxo-MINP about 4.3 hours, 
7OH-MINP about 4.4 hours and 7cx-MINP about 4.3 hours. 
37 % of the DINP dose was excreted in the first 24 hours mainly as MINP (26.7 %) 
followed by 7OH-MINP (4.6 %), 7cx-MINP (4.2 %) and 1.4 % (oxo-MINP). On the 
second day, 13.8 % DINP (10.1 % MINP, 1.7 % 7OH-MINP, 1.4 % 7cx-MINP, 0.6 % 
oxo-MINP) was eliminated by urine.  
 
Pig 2 
Dust: 
The primary metabolite MINP had the mean maximum concentration at 3.3 ± 1.1 
hours post dose. The secondary metabolites oxo-MINP and 7OH-MINP reached their 
maximum concentration after 2.3 ± 0.6 hours. The mean of tmax for 7cx-MINP was 2.7 
± 1 hours after dust application. The half-life time during the first elimination phase 
was estimated for MINP about 4.2 ± 2.1 hours, 5.4 ± 3.7 hours for oxo-MINP, 2.8 ± 
0.8 hours for 7OH-MINP, 5.5 ± 4.8 hours for 7cx-MINP. The second elimination 
phase occurred 11 - 24 hours post dose with the following half-life time: 4.4 ± 0.9 
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hours for MINP, 3.7 ± 2.1 for oxo-MINP, 21.4 ± 14.2 hours for 7 OH-MINP, 6.6 ± 6 
hours for 7cx-MINP. 53 ± 28 % of the applied dose were excreted within 24 hours as 
43 ± 30 % MINP, 5 ± 2 % 7cx-MINP, 3.5 ± 0.6 % oxo-MINP, 1.1 ± 0.5 % 7OH-MINP. 
On the second day only 2.6 ± 1.8 % DINP as 2.4 ± 2 % MINP, 0.1 ± 0.11 % 7cx-
MINP, 0.1 ± 0.04 % oxo-MINP, 0.01 ± 0.01 % 7OH-MINP were excreted.  
Food: 
After 24 hours the maximum concentration was reached. The half-life was 
determined as 3.1 hours (MINP); three hours (oxo-MINP and 7cx-MINP) and 3.3 
hours (7OH-MINP). Within the first 24 hours, 35 % of the DINP dose as 27 % MINP, 
4.5 % 7cx-MINP, 2 % 7OH-MINP, 1.6 % oxo-MINP whereas on the second day 18.4 
% DINP (14.1 % MINP, 2 % 7cx-MINP, 1.2 % 7OH-MINP, 1 % oxo-MINP) was 
excreted. 
 
Pig 3  
Dust: 
The mean of tmax was for all DINP-Metabolites 4 ± 1.1 hours after dose application. 
The first half-life time for the metabolites was 6.5 ± 2.6 hours for MINP, 6.1 ± 3 hours 
for oxo-MINP, 4.7 ± 2.4 hours for 7OH-MINP and 4.6 ± 2.3 hours for 7cx-MINP. The 
second elimination phase was determined 10 to 24 hours poste dose, the half-life 
times were for MINP at 6 ± 2 hours, oxo-MINP: 6.5 ± 1.9 hours, 7OH-MINP: 6.7 ±3 
hours, 7cx-MINP: 7.7 ± 3.3 hours. 
Within the first 24 hours 46.7 ± 32 % of the applied Dose were excreted as 40.5 ± 
31.4 % MINP, 2.7 ± 1.1 % 7cx-MINP, 2.4 ± 0.4 % oxo MINP, 1.1 ± 0.4 % 7OH-MINP. 
24 - 38 hours after the dust application only 5 ± 4.5 % DINP were excreted as 4.3 ± 
4.3 % MINP, 0.2 ± 0.15 % 7cx-MINP, 0.3 ± 0.1 % oxo-MINP  
Food: 
Tmax was noticed 24 hours post dose. The half-life time was estimated 5.8 hours for 
MINP, 6.4 hours for 7OH-MINP, 6.3 hours for 7cx-MINP and 7 hours for oxo-MINP.  
During the first 24 hours 37 % of the applied DINP dose was excreted as 33 % MINP, 
2.2 % 7x-MINP, 1.8 % oxo-MINP and 0.9 % 7OH-MINP. On the second day 18.8 % 
DINP was eliminated (15.8 % MINP, 1.2 % 7cx-MINP, 1.1 % oxo-MINP, 0.7 % 7OH-
MINP). 
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Pig 4  
Dust: 
Three hours after dose application tmax of MINP was reached. In the case of oxo-
MINP the mean tmax was: 7.7 ± 11 hours, 3 ± 1.4 hours for 7OH-MINP and 3.2 ± 1.2 
hours for 7cx-MINP. The first half-life time was estimated as 5.8 ± 1.7 hours for 
MINP, 4.3 ± 1.1 hours for oxo-MINP, 4.6 ± 1.5 hours for 7OH-MINP and 6.2 ± 3.8 
hours 7cx-MINP. The second half was determined 14 to 24 hours post dose and was 
calculated as: 5.4 ± 2 hours for MINP, 6 ± 3 hours for oxo-MINP, 5.3 ± 2.9 hours for 
7OH-MINP, 5 ± 2.4 for 7cx-MINP. 
In the first 24 hours, 30.5 ± 20.4 % of the administrated dose were excreted as 22 ± 
21 % MINP, 3.6 ± 1.3 % 7OH-MINP, 2.7 ± 1.2 % 7cx-MINP and 2 ± 1 % oxo-MINP. 
In the collection period of 24-38 hours only 2 ± 1.1 % DINP were eliminated as 1.6 ± 
1.4 % MINP, 0.13 ± 0.1 % oxo-MINP, 0.16 ± 0.13 % 7OH-MINP, 0.13 ± 0.1 % 7cx-
MINP.  
Food: 
The highest concentration was observed 24 hours after dose. The eliminated half-life 
varies from 5.8 hours (7cx-MINP), 6.1 hours (MINP), 7.6 hours (oxo-MINP) to 8.2 
hours (7OH-MINP).  
67.5 % of the DINP dose were excreted within 24 hours (62.6% MINP, 2.2 % 7OH-
MINP, 1.8 % 7cx-MINP, 0.8 % oxo-MINP), whereas on the second day 24.3 % of the 
applied dose were eliminated as 22.6 % MINP, 0.8 % 7OH-MINP, 0.6 % 7cx-MINP 
and 0.3 % oxo-MINP.  
 
Pig 5  
Dust: 
The highest concentration was determined for all metabolites at 3.7 ± 1.7 hours post 
dose. 
The elimination half-life time was calculated for MINP, oxo-MINP, 7OH-MINP and 
7cx-MINP with: 4.1 ± 0.7 hours, 8.4 ± 3.7 hours, 8.3 ± 2.6 hours and 5.7 ± 1.3 hours 
respectively. 24 hours post dose, the second elimination half-life time was 
determined with 4.7 ± 1 hours, 3.3 ± 0.5 hours, 6.6 ± 6.8 hours and 2.4 ± 1.1 hours 
for MINP, oxo-MINP, 7 OH-MINP and 7cx-MINP.  
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In the first 24 hours, 37 ± 19 % of the dose were excreted as 29 ± 20 % MINP, 3.1 ± 
1.4 % oxo-MINP, 2.6 ± 1 % 7cx- and 2.1 ± 0.5 % 7OH-MINP. After 24 hours 2.2 ± 1.3 
% of the applied dose were excreted as 1.8 ± 1.3 % MINP, 0.2 ± 0.1 % oxo-MINP, 
0.15 ± 0.04 % 7OH-MINP and 0.05 ± 0.04 % 7cx-MINP.  
Food: 
The maxima of MINP, oxo-MINP, 7OH-MINP and 7cx-MINP were reached after 24 
hours post dose. The half-life was determined as followed 7.8 hours (MINP), 14 
hours (oxo-MINP), 15 hours (7OH-MINP) and 8.6 hours (7cx-MINP).  
20 % of the applied DINP dose was eliminated within the first sampling day: In detail: 
16.2 % MINP, 1.9 % oxo-MINP, 1 % 7cx-MINP and 0.8 % 7OH-MINP. On the second 
sampling day 7.7 % DINP was eliminated (5.7 % MINP, 1 % oxo-MINP, and 0.5 % 
7cx-MINP and 7OH-MINP.  
 
Pig 6  
Dust: 
Compare to other pigs, tmax was delayed 9.5 ± 10 hours for MINP and oxo-MINP. 
7OH-MINP and 7cx- MINP had their tmax at 9.2 ±10 hours. The first estimated half-life 
for MINP, oxo-MINP, 7OH-MINP and 7cx-MINP was 4.7 ± 2.3 hours, 6.1 ± 4.7 hours, 
4.6 ± 2.2 hours and 4.9 ± 3 hours respectively.  
The second half-life time appeared 24 - 28 hours post dose, with 4 ± 0.8 hours, 4.5 ± 
0.4 hours, 4.2 ± 0.8 hours, and 4.6 ± 1 hours for MINP, oxo-MINP, 7 OH-MINP and 
7cx MINP.  
Within in the first 24 hours, 36 ± 7.3 % DINP were excreted as 25 ± 10 % MINP, 4.2 ± 
2.7 % oxo-MINP, 3.6 ± 1.6 % 7OH-MINP and 3.1 ± 1.3 % 7cx-MINP. On the second 
day 4.5 ± 2 % DINP were eliminated as 3 ± 1.3 % MINP, 0.6 ± 0.4 % oxo-MINP, 0.48 
± 0.3 % 7OH- MINP and 0.35 ± 0.31 % 7cx-MINP.  
Food: 
The highest concentration for MINP and oxo-MINP was determined at 24 hours, for 
7OH-MINP 28 hours and for 7cx-MINP 36 hours post dose.  
The elimination half-life time was calculated for MINP, oxo-MINP, 7OH-MINP and 
7cx-MINP 6.1 hours, 7.8 hours, 7.3 hours and 0.7 hours respectively 
Within the first 24 hours, 31.4 % of the applied DINP dose was excreted mainly as 24 
% MINP, followed by 3.5 % 7OH-MINP, 2.4 % 7cx-MINP and 1.5 % oxo-MINP, from 
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24 hours to 38 hours 17 % DINP was found in urine (12.5 % MINP, 2.3 % 7OH-
MINP, 1.4 % 7cx-MINP and 1 % oxo-MINP. 
 
Pig 7 
Dust: 
MINP reached their maximum concentration after three hours, similar to 7OH-MINP 
(2.6 ± 0.5 hours). Oxo-MINP and 7cx-MINP had their tmax at 8.25 ± 10.5 hours post 
dose. The first estimated half-life was 6 ± 2.6 hours for MINP, 9.5 ± 8 hours for oxo-
MINP, 8.5 ± 6.2 hours for 7OH-MINP and 8.2 ± 7 hours for 7cx-MINP. 
The second half-life (24 - 28 hours post dose) was estimated as 4.7 ± 1.4 hours for 
MINP), 5 ± 1.5 hours for oxo-MINP, 5 ± 1.8 hours for 7-OH-MINP and 4.2 hours for 
7cx-MINP. 
On the first day 59 ± 28 % DINP was eliminated by urine as 46 ± 32 % MINP, 5.6 ± 
2.7% 7cx-MINP, 3.5 ± 2.1 % oxo-MINP and 4.2 ± 4.9 % 7OH-MINP. On the second 
day, 5.5 ± 2.2 % DINP of the administrated dose were found in urine. The main 
metabolite was 4 ± 2.8 % MINP followed by 0.4 ± 0.3 % oxo-MINP, 0.4 ± 0.3% 7cx-
MINP, 0.5 ± 0.2 % 7OH-MINP.  
Food: 
After 24 hours the maximum concentration was reached. The half-life was 
determined for 7.4 hours MINP, 7.5 hours oxo-MINP, 8 hours 7cx-MINP, 8.2 hours 
7OH-MINP.  
22.7 % MINP, 3.5 % 7cx-MINP, 1.8 % oxo-MINP and 0.8 % 7OH-MINP (∑28.8 % of 
the applied DINP dose) were eliminated in the first 24 hours. Only 7 % of the DINP 
dose was found in urine as 5.4 % MINP, 0.8 % 7cx-MINP, 0.5 % oxo-MINP, 0.2 % 
7OH-MINP on the second day 
 
A detail description of the toxicokinetic parameters, concentration maximum (Cmax) 
and it’s time appearance (tmax), half-life time (t½) in the first excretion and second 
period (24 hours plus second t ½) are given in Table A7. 
 
The following figures reperesent the toxicokinetic time course of every pig with each 
dust sample and food sample. 
 
 113 
 
Table A7. Detail description of kinetic parameters of DINP metabolism [Cmax in µg; tmax and t½ in hour] 
Dust  Pig MINP Oxo-MINP 7OH-MINP 7cx-MINP 
  cmax tmax  t½  cmax tmax  t½  cmax tmax  t½  cmax tmax  t½  
A 1 56.6 3 7 24+4 1.4 3 4 - 1.7 3 7 24+3 2.8 3 7 24+4.6 
 2 64.6 2 7 24+6 2.1 2 11 24+2 0.7 2 4 11+7 2.8 2 13 14+15 
 3 41 3 4 24+7 1.3 3 7 24+7 0.6 3 7 10+5 1.8 3 5 24+7 
 4 45.1 3 5 24+8 1 2 11 3.4 2 3 14+7 2.5 5 11 
 5 45.8 4 3 24+4 2.3 4 5 24+4 1.1 4 7 24+17 1.2 4 18 
 6 25 3 7 24+4 1 3 12 24+5 1.8 2 7 24+4 1.3 2 6 24+4 
 7 99.1 3 4 24+5 3 3 5 24+5 1.3 3 - 4.6 3 4 24+4 
C 1 49.8 3 3 24+5 1.6 3 3 3.4 3 3 24+5 7.5 3 4 24+5 
 2 86.6 2 2 24+4 4.5 2 2 12+6 1 2 3 5.3 2 2 24+2 
 3 97.2 5 10 24+4 3.3 5 8 16+7 1.1 5 3 12+6 5 5 4 12+11 
 4 31.7 3 7 24+3 1.7 24 2 3.1 5 7 24+2 1.6 3 12 24+2 
 5 25.3 6 5 24+6 1.1 6 14 24+2 1.5 6 12 24+3 1.9 6 6 24+2 
 6 34.3 8 2 28+3 1.5 8 2 28+4 3.6 8 2 28+3 2.7 8 2 24+6 
 7 99.3 3 4 24+6 5.1 3 4 24+6 3.4 3 4 24+7 14 3 4 26+5 
D 1 24 4 5 24+4 3.1 4 6 24+4 7 2 5 24+4 10 2 6 24+4 
 2 63.5 4 4 24+4 10 3 5 24+4 5 3 4 24+3 18 3 4 24+5 
 3 40.6 5 6 24+8 4.2 5 2 14+8 2.6 5 2 14+12 3.3 5 2 14+6 
 4 28 3 4 24+4 4.7 2 5 24+3 11 2 4 24+4 6.5 5 4 24+5 
 5 64.5 3 4 24+4 7.2 3 6 24+3 4.4 3 6 24+3 9 3 4 24+2 
 6 33.1 24 4 7 24 5 6 24 5 8.2 24 4 
 7 56.6 3 8 24+4 11.5 24 4 5.4 2 5 24+4 17.7 24 4 
E 1 46.7 3 6 24+5 8.8 3 7 24+4 42.7 3 5 24+4 33.3 3 6 24+4 
 2 122.2 4 4 24+4 24 2 4 24+4 1.9 2 3 14+14 10.1 4 3 24+4 
 3 36.3 3 6 24+4 8.3 3 8 24+4 6.1 3 7 24+4 12.7 3 7 24+4 
 4 45.8 3 7 24+6 12 3 5 12+9 20.4 3 4 12+8 11.6 3 5 12+8 
 5 48.1 2 4 24+4 17 2 9 24+4 14.2 2 8 24+4 11.8 2 6 24+4 
 6 116.5 3 5 24+5 31.8 3 6 24+5 65.8 3 5 24+5 38.3 3 7 24+4 
 7 37.6 3 9 28+3 7.1 3 19 28+3 8.8 3 16 28+4 11.7 3 16 28+3 
Food 1 52.2 24 4 2.7 24 4 8.5 24 4 8.4 24 4 
 2 72.2 24 3 4.8 24 3 5.9 24 3 14.6 24 3 
 3 68.8 24 6 4.5 24 7 2.4 24 6 5.6 24 6 
 4 27 24 6 1.4 24 8 3.1 24 8 3.7 24 6 
 5 19.7 24 8 2.8 24 14 1.2 24 15 1.9 24 9 
 6 47.1 24 6 3.1 24 8 7.1 28 7 6.5 36 1 
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 7 23 24 7 2.2 24 7 0.8 24 8 3.8 24 8 
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No BBzP were detected. 
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